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Background: The relationship between mental health, quality of life (QOL) and cancer 
risk/mortality has not been adequately investigated. Psycho-neuro-immunology model 
has been hypothesized to provide links between psychological and physiological 
features of cancer risk/progression. Published findings are inconclusive. 
 
Objective: This thesis aimed to examine the association between psychological factors 
and cancer risk/mortality in elderly population (STUDY I&II), describe QOL in long-term 
cancer survivors (STUDY III), demonstrate response shift phenomena (STUDY IV) and 
explore psycho-neuro-immunological model between depression, cancer and ageing 
through inflammatory cytokines (STUDY V). 
 
Methods: The studies were based on data from three population-based cohorts in 
Singapore: the Singapore Longitudinal Aging Study (SLAS) (STUDY I, III & V), the National 
Mental Health Survey of the Elderly (NMHS-E) (STUDY II), and breast cancer patients 
recruited from National Cancer Centre (STUDY IV). Depression was determined by the 
Geriatric Mental State (GMS), and Geriatric Depression Scale (GDS). QOL was assessed 
by Functional Assessment of Cancer Therapy – Breast (FACT-B) in breast cancer patients. 
Inflammatory cytokines assessed including Tumour Necrosis Factor Alpha (TNF-α), 





STUDY I: Poor self-reported mental health was significantly associated with an elevated 
risk of overall cancer incidence (HR=1.42), in female breast cancer (HR=2.96), and in 
male lung cancer (HR=3.45). 
 
STUDY II: Depression was significantly associated with increased mortality hazard 
(HR=2.38) in cancer survivors. The mortality risk associated with depression among long-
term cancer survivors who did not die within 5 years after diagnosis remained 
substantially high (HR=4.69). In particular, depression was associated with increased 
mortality in female breast cancer survivors (HR=11.6). 
 
STUDY III: Long-term cancer survivors showed no statistical significant difference in QOL, 
life satisfaction level and depression level compared with their age-matched 
counterparts without cancer history. 
 
STUDY IV: (1) Recalibration: Comparing current and Then-test QOL total scores of FACT-
B, statistically significant different was only shown during chemotherapy period. Then-
test QOL score was significantly lower than current score, indicating worse QOL level. (2) 
Repriorization: There were statistically significant changes in the importance of PWB, 
EWB and FWB domains over the four assessments. (3) Reconceptualization: Financial 
concern was the most common concern mentioned except disease prognosis. At later 
IX 
 
assessment periods, the concerns were shifted to spiritual aspects, career prospects and 
mental well-being. 
 
STUDY V: Statistically significant difference of TNF- α level was found between elderly 
with/without depression. After stratifying depression into three levels, TNF-α level was 
significantly associated with depressive level. After grouping participants by age and 
depression, TNF-α level in old-old with depression group were significantly higher than 
the others after adjusting for confounding variables. There was no significant 
association of cancer history with cytokines. 
 
Conclusions:  
Psychological factors, especially depression, should be considered as a prognostic marker of 
cancer risk/survival in elderly population. Long-term cancer survivors reported similar 
QOL to their age-matched non-cancer counterparts. QOL is clearly affected by response 
shift, which may have an important impact on the interpretation of HRQOL changes. 
Inflammatory cytokine, elevated with depression, provides evidence base for the 
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CHAPTER 1: INTRODUCTION 
 
1.1 Cancer and Ageing 
 
Cancer is a principal cause of death and morbidity all over the world [1], 
accounting for 7.6 million deaths (around 13% of all deaths) in 2008. In Singapore, 
cancer is also the Number 1 killer in recent years like other developed countries, 
constituting more than 30% of total deaths in 2012 and 2013[2]. Rising standards of 
living, high standards of education, good housing, safe water supply and sanitation, high 
quality medical services and the active promotion of preventive medicine, have all 
helped to significantly boost the health of Singaporeans. With significantly prolonged 
life expectancy in recent decades, unfortunately, the incidence of cancer is climbing 
continuously. [3] According to Singapore Cancer Registry Annual Report 2014[2], in 2009 
– 2013, the age-specific incidence rate increased sharply from age 30 onwards and 
reached a peak in age 60 – 69 before gradually declining from age 70 onwards. About 60% 
of all cancers occur in people aged 65 years and above [4].  
 
1.2 Depression and Quality of Life in the Elderly 
 
When a person reaches his old age, changes often come—retirement, the death 
of loved ones, increased isolation, medical problems, which lead to depression and 
other psychological problems that may eventually result in poor quality of life. Among 
older adults, poor mental health functioning and poor quality of life are widely 
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recognized to be common, [5-7] due to these changes of social roles and profound 
decline of physical functioning. Depression and other psychological problems not only 
prevent those from enjoying their life that they used to, but their effects go far beyond 
emotions. Poor psychological functioning and quality of life impact their energy, sleep, 
appetite, and resultant poor physical health including cancer.  
 
1.3 Mental Health Functioning and Cancer Development 
 
The link between mental health and cancer risk is a subject of persistent interest 
and debate. Although there is no proof that one disease causes the other, psychosocial 
risk factors for cancer, including different aspects of mental health, have been 
investigated in numerous epidemiological studies. Mental health functioning has been 
more commonly used as an important cancer outcome, instead of a cancer risk factor. 
Meanwhile, there is considerable support among members of the public and health 
professionals for the view that poor mental health functioning, especially depression, is 
an aetiological factor in the later development of cancer. However, with limited and 
inconsistent evidence, it is still debatable whether poor mental health functioning, 
including depression, should be appropriately considered a causal risk factor or merely a 
risk marker related to cancer.  
 
1.3 Depression, Quality of Life and Mortality in Cancer Survivors 
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With earlier diagnosis and more effective treatment, currently two-thirds of 
adults who have a cancer diagnosis are expected to survive 5 years or more after 
diagnosis,[8] and the numbers are expected to increase with global population ageing. 
“Cancer survivors” have been described as a group of people who "live with or beyond 
cancer"[9]. They have had cancer in the past, and typically have completed initial cancer 
treatment with no evidence of active disease; or they may be living with cancer that is 
progressing and may be receiving treatment, but are not terminally ill. Cancer 
survivorship has emerged as an important area of oncology since 1990s. 
 
It is now recognized that a sizeable proportion of cancer survivors develop 
significant and lasting psychological sequelae, like depression.[10]  In addition, cancer 
survivors are more likely to experience suicide ideation, related to issues of pain and 
physical distress.[11] 
 
Notwithstanding that up to 70% of members of the public, 85% of cancer 
patients and 71% of oncologist endorsed the belief that psychological factors, especially 
depression, adversely affected cancer progression and mortality,[12] strong support 
from empirical evidence is still lacking. It has been demonstrated that poor mental 
health functioning, as measured one major aspect of quality of life, is associated with 
adverse outcomes in disease-specific populations, for example, patients with atrial 
fibrillation, leukemia and chronic obstructive pulmonary disease. Accumulating 
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evidences suggested that interventions to improve psychological well-being and quality 
of life may possibly prolong survival time in cancer patients.  
 
1.4 Quality of Life and Response Shift Phenomenon in Cancer Survivors 
 
During the last two decades, there has been increasing recognition of the need 
to complement the biomedical evaluation criteria for cancer treatment with the 
assessment of the quality of life (QOL) experienced as a result of the disease and its 
treatment.[13] QOL has been found to be associated with adherence to treatment [14] 
and prognosis [15, 16] and is now recognized as an important cancer outcome.  
 
Over the past decades, numerous studies have addressed the physical, 
psychological, emotional, social, as well as sexual well-being of cancer patients with the 
focus largely on the period of treatment following diagnosis, not many years post 
diagnosis. However, the long-term survival of cancer patients has risen dramatically 
during this period, yet little is known about the quality of life experienced by these 
survivors. Recently, not only professional researchers and government service providers, 
but a large number of cancer survivors many years post cancer treatment  have 
heightened interest in studying long-term effects of cancer and its treatment on quality 
of life. With the increasing number of long-term cancer survivors, the need to assess 
their QOL is becoming more important and meaningful. 
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In addition, a recent FDA revision, however, revealed problems in using QOL in 
cancer clinical trials[17]. There are a number of methodological problems that plague 
longitudinal QOL research. One of the main problems raised is response shift 
phenomenon emerging when the assessment of QOL was required repeatedly over time. 
 
When patients confronted with a life-threatening or chronic disease, they are 
faced with the necessity to accommodate to their illness. As an important mediator of 
this adaptation process, response shift would bring about changes within patients 
regarding their internal standards, values and the conceptualization of QOL, which 
would affect standard psychometric indices, such as reliability and validity.  
 
1.5 Inflammatory Cytokines, Depression, Cancer and Ageing 
 
Inflammation has classically been viewed as an acute (short term) response, 
which is canonically defined as a protective immune-vascular response to promote host 
repairs of tissue injury and infection. In the last decades, striking advances were made in 
our understanding of the biochemical and cellular mechanisms induced by acute 
inflammation, whilst the knowledge of the intracellular programs regulated by chronic 
inflammation advanced at a much slower rate.[18] Nevertheless, the spectrum of 
prevailing inflammatory conditions has shifted from acute to chronic inflammatory 
states since the end of 20
th
 century, significantly contributing to the pathogenesis of 
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modern diseases such as obesity, diabetes, neurodegenerative diseases, cancers[19] 
and psychological diseases (e.g. depression)[20].  
 
Cancer and cancer therapy can collectively result in inflammation and cytokine 
production, which have been associated with occurrence of depression. Conversely, 
depression supports a chronic activated hypothalamic-pituitary-adrenal (HPA) axis and 
further determines cortisol and adrenal disturbances, as well as immune dysfunction 
and increased cytokine production. Through these processes, depression is also 
associated with cancer development and outcome. 
 
The idea that psychological states can affect the outcome of human disease is 
not a new one. Depression, which is common in elderly population, contributes 
substantially to disease burden. Better understanding of the role of biological factors, 
such as inflammation, is recognised as increasingly important to enhance our knowledge 
of the aetiology and pathophysiology of depression. Evidence for the role of raised 
inflammatory markers has been accumulated over the past 20 years and many 
inflammation measures have been identified as potentially significant, including 
cytokines (e.g. interleukin-6, IL-6 and tumour necrosis factor-alpha, TNF-α) and acute 
phase reactant proteins (e.g. C-reactive protein, CRP). The exact biological mechanisms 
linking depression to inflammatory cytokine changes are still unclear.  
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Thus, we sought to assess the association between depression, cancer, age, 
gender and other demographic factors on plasma levels of TNF-α, IL-6 and CRP in a 
community living elderly population from Singapore Longitudinal Ageing Study cohort. 
 
1.6 Hypothesis and Research Objectives 
 
Psycho-oncology is an area of multi-disciplinary interest and has boundaries with 
the major specialities in oncology, for example, the clinical disciplines (surgery, 
medications), epidemiology, immunology, biology, pathology as well as psychiatry and 
psychology. It is concerned with the psychological, social, behavioral, and ethical aspects 
of cancer. Psycho-oncology addresses the two major psychological dimensions of cancer: 
the psychological, behavioral and social factors that may influence the disease process 
(e.g. incidence and survival) and the psychological responses of patients to cancer at all 
stages of the disease (e.g. depression and quality of life assessments).  
 
The overall aim of the thesis was to investigate the associations between 
psychological status, particularly of depression, and cancer risk / mortality in the elderly, 
gain a better understanding of quality of life in long-term cancer survivors, address 
response shift phenomenon in quality of life assessment, and explore the underlying 
biological linkage between cancer, depression and ageing through inflammatory 
cytokines. 
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The specific objectives of the studies were: 
(1) To investigate the association between poor mental health status with late-life 
cancer incidence risk in a population-based cohort record linkage follow-up study of 
older adults in the Singapore Longitudinal Ageing Studies (SLAS) [21].   
 
(2) To investigate the association between depression and mental health status with 
mortality in cancer survivors in a community-living cohort of older adults  
 
(3) To investigate quality of life between community living long-term cancer survivors 
and their non-cancer age-matched counterparts in SLAS cohort 
 
(4) To study changes in the quality of life and describe the occurrence of response shift 
in the breast cancer patients at critical phases of their disease trajectory 
 
(5) To explore primary evidences through inflammatory cytokines linking depression, 
cancer and immune ageing in a subgroup of SLAS cohort 
 




Despite aging cannot be considered directly responsible for the neoplastic 
processes, the incidence of cancer generally and undeniably increases with age. The 
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cellular and molecular mechanisms underscoring the link between cancer and aging 
have been efficaciously summarized in several reviews[22-24]. Besides mutation burden, 
telomere dysfunction, impairment of DNA repair and alterations in proliferative 
homeostasis, several disturbances in the immune system have been consistently 
described in aging[25]. It may affect both cell-mediated and humoral immune responses 
with a downregulation of specific immunity and a nonspecific activation of pro-
inflammatory pathways. Similar immune dysregulations are also observable in cancer, 
where a persistent humoral immune response exacerbates the activation of innate 
immune response and inflammatory pathways, which concur in promoting cancer 
development[26, 27]. Interestingly, immune dysregulation can be considered as one of 
the factors explaining the link between cancer and depressive symptoms. The latter one 
has also been suggested to be associated with poorer cellular immune function[28, 29] 
and cytokine dysregulation[30-32]. However, more research is needed to clarify the 
mechanisms between depressive symptoms, cancer development and progression upon 
the background of ageing, in virtue of its ability of altering immune competence and 
promoting inflammation. 
 
2.2 Study I: Psychological Status and Cancer Incidence 
 
It is uncertain whether poor mental health status should be considered as an 
etiologic factor in the development of cancers, [33] although there is widespread 
perception of this link in the general populace and also among health professionals [12]. 
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Psychosocial risk factors including depression for cancer have been investigated in 
epidemiological studies, but the findings were contradictory. [34-38] The relationship 
between mental health and cancer risk therefore remains poorly understood, altered 
immune function is believed to play an important role as a common pathophysiologic 
substrate for depression, cancer and ageing. 
 
Digging into the research literature, only two meta-analyses (published in 1994 
and 2007) supported a tendency towards a small but marginally significant association 
between depression and subsequent risk of developing malignant neoplasms [37, 38]. 
Based on eight eligible studies with complete crude data on overall cancer, Oerlemans 
ME [38] and his team pooled a summary relative risk (RR) of 1.19 (1.06-1.32) using 
depression as a predictor of cancer. However, the statistically significant association 
disappeared after adjustment for potential confounders (RR=1.12 (0.99-1.26). Similarly, 
McGee R’s meta-analysis indicated a small but significant association between 
depression and the later development of cancer, but he also commented that the 
practical significance of this association for the prevention of cancer is negligible[37]. 
 
Among studies with longer follow-up time, more supportive and confident 
evidences emerged among several cancer specific researches. In Oerlemans ME’s meta-
analysis[38], no significant association was initially found between depression and 
subsequent breast cancer risk based on seven heterogeneous studies. Subgroup analysis 
of the studies with a follow-up of ten years or more, however, resulted in a statistically 
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significant summary relative risk of 2.50 (1.06-5.91). Another 24 year cohort study 
conducted in the Baltimore area also suggested that DIS/DSM-III major depression was 
associated with a higher risks for overall cancer (HR: 1.9, 95% CI: 1.2, 3.0) and a more 
statistically significant increased risk for breast cancer (HR: 4.4, 95% CI: 1.08, 17.6) 
among women [39]. In 2005, an U.S. research team conducted a study on the 
association of depressive symptoms and prospective incidence of colorectal cancer in 
women. It was found that depressive symptoms were associated with an approximately 
40 percent excess risk of incident colorectal cancer in women over 8 years of follow up 
[34].  
 
This hypothesis is challenged by epidemiological research findings by several 
authors. A research group in Denmark (Dalton SO [35]) investigated cancer risk of 
patients hospitalized for depression in a nationwide Danish cohort study followed up 
from 1969 to 1993. Other than deleterious effect that depression could have on lifestyle 
factors, their data provided no support for the hypothesis that depression 
independently increases risk of cancer. Liang [36] and coworkers used the data of the 
National Health Insurance system of Taiwan to test the same hypothesis in Taiwan 
population. The results also did not show a statistically significant relationship between 
depression and cancer risk; however, almost all the relative risk estimates tended 
toward a positive association for overall cancer and site-specific cancers including 
hematologic malignancy, lung cancer, breast cancer, uterus, cervical, ovary, and vaginal 
cancer, prostate cancer, and brain cancer. 




The cumulated evidence reveal a potential that depression and mental health 
status may favour the development of overall cancer in the long term, and also suggest 
specificity to the association between depression and cancers, which provides support 
to hypotheses about a common biological pathway (possibly hormonally mediated) 
between depression and cancer. Although not the subject of the present proposed 
study, there is supporting evidence of biological plausibility from recent studies 
suggesting that complex neuroimmunobiological interactions play a mediational role 
between poor psychological status and cancer incidence/mortality.  
 
2.3 Study II: Depression and Mortality in Cancer Survivors 
 
Depression is the most common comorbid disabling syndrome that affects 
approximately 15% to 25% of cancer patients.[40, 41] It is reported in 2014 that 16.8% 
of cancer patients in Singapore hospital is diagnosed with major depression, while 9.5% 
were found to have generalized anxiety disorder, three to ten times higher than their 
corresponding prevalence rates in the general population.[42] In a large population-
based study of long-term cancer survivors of adult-onset cancer of 5 years or more, the 
prevalence of serious psychological distress (5.6%) was significantly higher than among 
respondents who were never diagnosed as having cancer (3.0%).[43] 
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Early meta-analysis [44-47] indicate either an inconsistent effect or at best a 
consistent but small effect of depression in predicting mortality among cancer patients. 
Based on data from 25 independent studies, mortality rates were up to 25% higher in 
patients experiencing depressive symptoms (RR unadjusted = 1.25; 95% CI, 1.12-1.40; P 
< .001), and up to 39% higher in patients diagnosed with major or minor depression (RR 
unadjusted = 1.39; 95% CI, 1.10-1.89; P = .03). In support of a causal interpretation of 
results, there was no evidence that adjusting for known clinical prognostic factors 
diminished the effect of depression on mortality in cancer patients.[47] There are 
considerable heterogeneity in the overall results, which are greater in studies with 
shorter duration of follow up (less than 5 years), and less in studies with longer follow 
up (5 years or more).  The meta-analysis also indicates a tendency for studies to show 
that the mortality effect to be stronger within the first 5 years of follow up and to 
weaken with longer follow up. Although the ideal length of follow-up to capture a 
survival effect is unclear, it is desirable to assess the survival effect be presented for 
both early and late follow-ups. 
 
A number of clinical research suggested that in the preoperative or immediate 
post-operative periods, poor psychological status, depression and/or anxiety was 
associated with higher cancer mortality after surgical management in patients with 
malignant astrocytoma and low-grade glioma,[48] digestive system cancer[49], lung 
cancer [44], and breast cancer [45] [50]. Nevertheless, several other research[51, 52] 
failed to support the conclusion that negative psychological status increases the risk of 
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mortality in cancer patients.  In a Japanese study conducted in 2008[51], the significant 
linear positive association between helplessness / hopelessness and depression with the 
risk of mortality in lung cancer patients no longer remained significant after adjustment 
for multiple clinical state variables. The authors commented that many studies are 
limited by a small number of subjects, and findings may be confounded by failure to 
control sufficiently for potential confounding variables such as socioeconomic variables 
and smoking status.  
 
Recent meta-analyses and prospective clinical studies gave us a bit more 
convincing evidence suggesting depression is associated with increased mortality and 
decreased survival of cancer patients.[53-55] A larger meta-analysis of 76 prospective 
studies confirmed the results prior obtained by Satin et al. and in addition concluded 
that depression and depressive symptoms predict mortality independent of cancer 
stage or site.[53] Also, an important survival advantage was noticed in non-depressed 
cancer patients compared to depressed cancer patients, especially in the case of 
metastatic breast cancer (28.5 months)[54] and advanced non-small cell lung cancer 
(7.2months).[55] 
 
2.4 Study III: Quality of life in Long-term Cancer Survivors 
 
Where diagnosis of a cancer was once often considered a death sentence, the 
majority of patients are now surviving cancer. In April 2014, Cancer Research UK 
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announced the 10-year survival rate for all cancers now averages over 50 per cent. 
Similarly, the most recent figures from the Australian Institute of Health and Welfare 
show that five year survival improved from 47 per cent in 1982-87 to 66 per cent in 
2006-10. Life expectancy of cancer patients has been significantly prolonged with 
improved early detection and treatment.  
 
Research suggested that cancer treatments can have long-term physical, 
psychological, social and cognitive effects that may influence QOL.[56-60] A review of 34 
publications on long-term survivors of adult-onset cancers documented that many 
survivors continue to experience negative effects of cancer and/or treatment on their 
daily lives well beyond the completion of therapy.[56] Sexual functioning and/or 
satisfaction and psychological functioning were found to be concerns for many survivors. 
Past systemic adjuvant treatment was reported by several studies to be associated with 
poorer functioning on different dimensions of QOL.[58] 
 
Several researches, on the other hand, documented positive coping strategies and 
enhanced quality of life in long-term cancer survivors.[56] They were reported to have 
similar QOL in most aspects to age-matched non-cancer controls many years post 
cancer diagnosis.[58, 61, 62] Omne-Ponten et al.[63] and Grassi and Rosti[64] measured 
QOL in cancer patients at more than one time point, and both studies found evidence that 
psychosocial dysfunction decreased over time. Long-term survival of breast cancer is so 
far the most extensively studied in this area because of the remarkable improvement in 
Department of Psychological Medicine                                     Jiang Min-Jun, HT090037M 
16 
 
detection and treatment of this disease. M Dorval et al.[57] also reached similar 
conclusion in breast cancer population that, in most domains and for women without 
further disease events after diagnosis, QOL does not seem to be permanently and globally 
impaired by breast cancer. Although arm problems and sexuality are still the two areas in 
which additional effort may be needed, breast cancer survivors who remain free of 
disease probably do not need organized late psychosocial follow-up to improve QOL. 
 
Current evidence supported the need to measure positive aspects of quality of life as 
well as problems in long-term cancer survivors. Also, study designs will be more 
accurate to measure QOL among community living survivors of cancer after adjusting for 
the effects of aging and comorbidity. 
 
2.5 Study IV: Response Shift Phenomena in Breast Cancer Patients 
 
In clinical trials, patients are assessed on their QOL over time. An example of a 
simple repeated assessment would be that the patient is assessed pre-treatment and 
post-treatment. According to Sprangers[65], such an assessment of QOL is based on two 
assumptions. The first assumption is that “patients have an internalized standard of 
measurement for the dimensions of QOL being assessed” and the second assumption is 
that “subjects’ internalized standard of measurement is stable and will not change over 
time”. However, these assumptions have been challenged. In the study performed by 
Breetvelt & Van Dam[66], it was found that despite having a severe chronic illness, 
patients were found to report a level of QOL neither inferior nor better than that of 
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healthy subjects or other patients with a less severe illness. Llewellyn-Thomas[67] 
observed that when compared to healthy subjects or people with benign diseases, 
cancer patients are more willing to undergo risky and toxic treatments with minimal 
chance of benefit. This indicated that patients with life threatening illnesses may have 
lowered their standards of tolerance and/or changed their values. In the study by 
Sprangers[68], patients who were undergoing radiotherapy were examined. It was 
found that patients who were experiencing diminishing levels of fatigue, 
“retrospectively amplified their pre-treatment level of fatigue, whereas patients whose 
fatigue had recently increased, retrospectively minimized their initial level of 
fatigue”[69]. Other studies by Lenert[70] and Bach and Tilton[71] have also shown 
paradoxical findings. The above examples are possible indicators that the response shift 
phenomenon could have been responsible.  
 
Response shift is a reaction to changes. In the example of a cancer patient, changes 
may be represented by the changes in his/her physical and functional abilities, changes 
in the environment, family and social life. In order to adapt and cope with these 
changes, the patient gradually adapts to the situation and becomes better at coping 
with it. Similarly with the symptoms or treatment side-effects, the patient also adapts 
and becomes better at coping with them. This results in a change in the patient’s 
underestimated perception of the symptoms. 
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Response shift bias was first introduced in early 1990’s when a lot of studies 
reported no difference of QOL between cancer patients and normal healthy population 
using self-report questionnaires.[66] Sprangers and Schwartz defined response shift 
through three components “as a change in the meaning of one’s self-evaluation of a 
target construct as a result of a change in the respondent’s internal standards of 
measurement (recalibration), a change in the respondent’s values (reprioritization) or a 
redefinition of the target construct (reconceptualization)”.[68]  
 
All the paradoxical findings have “large implications for QOL-based clinical trials”. 
Patients’ adaptations to treatment toxicities or even to improvement in health “may 
result in an inaccurate assessment of QOL over time” and “response-shift bias can affect 
adversely the validity of QOL assessments”[65]. Current QOL tools are only able to 
measure the current and recent status of QOL, and if these tools are used for 
comparison purposes across time, over the disease trajectory, the response shifts that 
occur in a patient may render assessments incomparable as the internal “units of 
comparison have changed”, and ”the comparison itself has lost its meaning”. This may 
result in problems with clinical interpretations of patients’ self-reported quality of life 
especially when they are used in clinical trials. Given the importance of QOL as an end 
point in clinical trials, it is therefore important to be able to assess and measure 
response shift especially when “treatment outcomes are being compared” in order to 
reveal any biases in the patients’ perceptions and judgments[65]. 
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Breast cancer is the most common female cancer in western countries, and the 
second leading cause of cancer deaths in women. In Singapore, more than 25% of all 
cancers diagnosed in women are breast cancers. Between 2009 and 2013, about 1,772 
women were diagnosed to have breast cancer in Singapore each year[72]. Therapeutic 
advances in breast cancer from surgery, radiotherapy, chemotherapy, and hormonal 
therapy have contributed to improvements in survival; five-year survival currently 
stands at 87% [73]. Many women who have had breast cancer can still live a normal 
lifespan. However, vast numbers of women with breast cancer continue to experience 
considerable physical and psychosocial dysfunction during and following treatment.  
 
2.6 Study V: Inflammatory Cytokines, Depression, Cancer and Ageing 
 
Global ageing means that the issues related to elderly care will become more 
prominent, especially with the potential for increasing numbers of cancer diagnoses and 
elderly cancer survivors. Large health care expenditures for a rapidly ageing population 
have stimulated scientific inquiry and heightened public awareness regarding ageing-
related issues. In recent decades, scientific and technological advances have resulted in 
more efficient treatment of acute diseases and changes in human habits contributing to 
a high increase in the prevalence of chronic inflammatory conditions.  
 
Spoletini and others in Italy published a systematic review in 2008 [33] and 
suggested that the role of immune dysfunction as a common pathophysiologic ground 
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of depression, cancer and ageing should be considered an emergent issue in oncological 
research. A chronic depressive state may favour the development and exacerbation of 
certain cancers, especially in elderly population that are at increased risk of immune 
dysregulation. As an example, a study published by Steel J.I. in 2007[74] found that 
depressive symptoms and decreased survival were associated with decreased NK cell 
numbers in patients diagnosed with hepatobiliary carcinoma, suggesting that NK cell 
numbers may mediate the relationship between depression and mortality. Such results 
have been questioned [75], hence more research is needed to clarify the link between 
immunological dysfunctions, clinically relevant depression, cancer incidence and 
mortality in the elderly.  
 
The association between depression, cancer and ageing is by no means 
incidental. Depression, as a prevalent condition, is reported to be related to all-cause, 
cardiovascular, and cancer morbidity and mortality.[76-78] The mechanisms responsible 
for these associations have yet to be elucidated but inflammatory processes are 
implicated. Recent studies suggest that complex psycho-neuro-immunological 
interaction might play a mediational role,[79] which discovered a link between 
depression, immunity and inflammation.[80, 81]  
 
Cancer, as a heterogeneous group of diseases with multiple causes, is suggested 
to be affected by psychological, behavioural, and immunological factors. Chronic 
inflammation and cancer are associated based on the accumulating evidences from 
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literature: some solid cancers arise at sites of chronic inflammation, whereas other solid 
cancers induce an inflammatory microenvironment.[82]  
 
It has recently been suggested that cancer-related inflammation may represent 
the seventh hallmark of cancer, in addition to the six hallmarks identified by Hanahan 
and Weinberg: self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis.[83, 84] 
 
The role of inflammation in cancer and depression is not well understood. 
Evidence mainly from animal models and human studies suggests that depression result 
in an impairment of the immune response and might promote the initiation and 
progression of some types of cancer.[85, 86] Through HPA activation, the mediators 
released during chronic inflammation suppress some non-specific and specific parts of 
the immune response including NK-cell activity, phagocytosis, production of 
inflammatory cytokines (i.e. IL-6, TNF-α, CRP).  
 
C-reactive protein is an annular, pentameric protein in the blood plasma, the 
levels of which rise in response to inflammation. This acute phase response occurs as a 
result of concentration of IL-6, in response to a wide range of acute and chronic 
inflammatory conditions.  It plays a role in innate immunity as an early defense system 
against infections. Raised level of CRP was suggested to represent an association with 
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depression by several studies.[20, 87] Though still lack of causality between elevated 
CRP level and increased cancer risk, it does not invalidate the potential clinical use of 
slightly increased CRP levels to predict risk of certain cancer types, and to improve 
stageing and treatment allocation in cancer patients.[88] 
 
IL-6 is an interleukin that acts as both a pro-inflammatory cytokine and an anti-
inflammatory myokine. IL-6 stimulates the inflammatory and auto-immune processes in 
many diseases. The epigenetic effects IL-6 have also been implicated in the pathology 
of depression.[20, 89-91] Advanced / metastatic cancer patients have higher levels of IL-
6 in their blood.[92] IL-6's role, as an anti-inflammatory cytokine, is mediated through its 
inhibitory effects on TNF-α and IL-1, and activation of IL-1ra and IL-10. 
 
TNF-α is a cell signaling protein involved in systemic inflammation and is one of 
the cytokines that make up the acute phase reaction. The primary role of TNF is in the 
regulation of immune cells. TNF, being an endogenous pyrogen, is able to induce fever, 
apoptotic cell death, cachexia, inflammation and to inhibit tumorigenesis and viral 
replication and respond to sepsis via IL1& IL6 producing cells. Dysregulation of TNF 
production has been implicated in a variety of human diseases including cancer and 
depression.[89, 93-95] 
 
For years, psychologists have studied negative psychological states associated 
with the development and prognosis of cancers, because of the particularly high 
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prevalence of mental disorders, such as depression, in patients with advanced cancer. 
Research combining immune-oncology and psycho-oncology is a novel area in medical 
science. Researchers have therefore not paid sufficient attention to this field.  
 
CHAPTER 3: METHOD 
 
3.1 Study I: Psychological Status and Cancer Incidence 
 
Participants and Medical Records 
 
The Singapore Longitudinal Ageing Study (SLAS) is a population-based 
prospective cohort study of aging and health in community-dwelling older adults in 
Singapore. A whole population sample of participants was identified through door-to-
door census in five contiguous districts in the South, East and West Region of Singapore 
with over-representativeness of the Chinese population. The eligible population 
consisted of all older persons, Singaporean citizens or permanent residents, aged 55 and 
older, excluding individuals who were not able to participate because of severe physical 
or mental illnesses or incapacity. The response rate was 78%. The cohort members were 
first recruited in 2004/2005. The National University of Singapore institutional review 
board approved the study, and informed consents were obtained from all participants.  
 
Record linkage with the National Cancer Registry identified participants with a 
registry record of malignant cancer diagnosed [International Classification of Diseases, 
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Ninth Revision, ICD-9] before their dates of recruitment into the study, and these 
subjects were excluded in this study. The final analytical sample consisted of 2620 
cancer-free participants, who were followed up for an average of 6 years from their date 
of recruitment to 31 December 2010. Incident cases of cancer among cancer-free 
participants in the cohort were ascertained by record linkage with the Singapore 
National Cancer Registry and death with National Death Registry through the National 
Registry of Diseases Office.  Person-months of follow-up time were calculated for each 
person until cancer diagnosis or censored for the period up till 31 December 2010. 
 
Baseline and Outcome Measurements: 
 
The mental health status of the study participants was assessed using the Mental 
Component Summary (MCS) score of the 12-item Short-Form (SF-12) Health Survey for 
mental health functioning and the 15-item Geriatric Depression Scale (GDS) score for 
depressive symptoms. In addition, we used the Physical Component Summary (PCS) 
score of the SF-12 to assess physical health functioning, as a control variable alongside 
the SF12-MCS, to assess the specificity of the relationship between mental health 
functioning status and cancer incidence.   
 
The 12-item Short-Form (SF-12) Health Survey version 2, an abbreviated version 
of the full SF-36 Health Survey version 2, is widely used in research as a generic 
instrument to assess mental and physical health functioning across a wide range of 
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medical conditions and health states. Response scores of the SF-12 are weighted and 
summed to provide easily interpretable scales for mental and physical health 
functioning. MCS and PCS are computed using the scores of twelve questions and range 
from 0 to 100, where a zero score indicates the lowest level of health and 100 indicates 
the highest possible level of health. Since no Singapore norms are currently available, 
PCS and MCS scores were calculated based on US norms. Participants whose had their 
SF-12 MCS or PCS scores within the lowest tertile (the lowest 33.3%) were considered to 
have poor mental or physical  health functioning, while participants whose had their SF-
12 MCS or PCS scores above the lowest tertile were considered to have normal mental 
and physical health functioning.  
 
Symptoms of depression were assessed using Geriatric Depression Scale (GDS) 
short form. It is a 15-question screening tool for depression in older adults taking five to 
seven minutes to complete. It consists of 15 questions requiring "yes" (1) or "no" (0) 
answers for depression assessment in older adults. The GDS has been validated in the 
local population as a screening instrument for depression[96]. A summed score equal to 
or greater than 5 is indicative of clinically significant depressive symptoms.    
 
Data collected at baseline for known risk factors of cancer incidence that were 
potential confounders in analyses included age, gender, housing type (a validated 
surrogate measure of socioeconomic status among Singaporeans), ever smoking status, 
body mass index and medical comorbidities.      






Poor mental / physical health status (SF-12 MCS / PCS lowest tertile) and 
depressive symptoms (GDS≥5) were modelled as primary independent variables of 
interest in survival analyses for time-to-event (cancer incidence). The time to first cancer 
incidence was plotted in hazard curves using Kaplan-Meier estimate and analyzed as 
dependent variable in Cox proportional hazard regression models. Data were censored 
for subjects who died or dropped out before the event of interest or since the last date 
of observation (December 31, 2010). Crude and adjusted hazard ratios and 95% 
confidence intervals (CIs) were estimated in Cox regression models, with checks for 
proportional hazards assumption and time-dependent covariate modelling as 
appropriate, and significance at p<.05. Covariates in the Cox regression models included 
demographic factors (gender, age, housing type); smoking history and BMI were 
evaluated in hierarchical models to determine whether physical factors changed the 
association between mental / physical health status, depressive symptoms and cancer 
incidence. Age, gender, housing type, BMI, smoking history and medical comorbidity 
were used as stratification variables in stratified Cox regression models. Pearson’s or 
Spearman’s correlation coefficients were used to evaluate the correlation between SF-
12 MCS, SF-12 PCS and GDS. All statistical analyses were performed using SPSS version 
18.0 software, and all statistical tests were two-sided with a P<.05 significance level. 
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3.2 Study II: Depression and Cancer Mortality 
 
Study participants and medical records 
 
The study participants in the population-based National Mental Health Survey of 
the Elderly (NMHS-E) in Singapore were a random nationally representative sample of 
older adults (aged 60 and above). The NMHS-E was conducted from 15 February 2003 to 
30 March 2004, and included 1,092 elderly who were Singapore Citizens or Permanent 
Residences. Details of the NMHS-E have been previously reported in a prior publication. 
[97-101] 
 
We performed record linkage of the survey cohort with the National Cancer 
Registry through the Singapore National Registry of Diseases Office and identified survey 
participants who were registered with a confirmed diagnosis of malignant cancer 
[International Classification of Diseases, ninth edition, ICD-9] diagnosed before the dates 
of their participation in the survey. Cancer survivors were defined as those elderly in the 
cohort who had cancer in the past and completed initial cancer treatment with no 
evidence of active disease. Based on the criteria, we identified 61 cancer survivors in 
this population sample and ascertained their mortality outcomes over the following 8 
years by ascertaining their subsequent vital status through record linkage with the 
National Death Registry of Singapore. Person-years of follow-up time were calculated 
for each person until their death or censored till 31 December 2011. 
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Baseline and Outcome Measurements: 
 
All participants were administered the Geriatric Mental State (GMS) Schedule, a 
standardized, semi-structured diagnostic interview instrument used to assess 
psychopathology for older adults [102, 103]. Diagnosis of depression is made by means 
of a computer-assisted system, the Automated Geriatric Examination for Computer 
Assisted Taxonomy (AGECAT) [104] using a hierarchical algorithm which corresponds to 
approaches to diagnosis made by psychiatrists. The GMS has been demonstrated to 
provide accurate diagnoses of recent psychiatric disorders in elderly people by 
generating levels of diagnostic confidence for determining ‘caseness’. A confidence level 
of zero denotes absence of depression disorder; levels of 3 to 5 (‘case’) meets clinical 
threshold criteria for DSM-IV diagnosis of depression; and levels of 1 or 2 (referred to as 
‘sub-case’) denotes probable subthreshold cases. The GMS was administered by trained 
psychiatric and community nurses and interviewers. The interviewers underwent 
extensive training using training vignettes, completed and co-rated four to six 
supervised training interviews each, and were closely supervised and monitored in the 
field. The trainers and supervisors were psychiatrists who were trained by psychiatrists 
at the Institute of Psychiatry, London. 
 
Diagnosis of threshold / subthreshold depression was made on the same date of 
interview. Survival time was calculated in three ways: 1) survival time before date of 
interview (DOI) since cancer diagnosis; 2) survival time after DOI to the event of interest 
(death) or last date of observation (December 31, 2012); 3) total survival time from 
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Depression diagnosis was modelled as the primary independent variable of 
interest in survival analyses for time-to-death. The time to death was plotted in survival 
curves using Kaplan-Meier estimate and analyzed as dependent variable in Cox 
proportional hazard regression models. Data were censored for subjects who dropped 
out before the event of interest or on the last date of observation (December 31, 2012). 
Crude and adjusted hazard ratios and 95% confidence intervals (CIs) were estimated in 
Cox regression models, with checks for proportional hazards assumption and 
significance at p<.05. Covariates in the Cox regression models included demographic 
factors (gender, age), social-economic status (housing type), smoking history and 
medical comorbidities. All statistical analyses were performed using SPSS version 18.0 
software, and all statistical tests were two-sided with a P<.05 significance level. 
 
3.3 Study III & V: Quality of life, Inflammatory Cytokines, Depression in 




The Singapore Longitudinal Ageing Study (SLAS) is a population-based 
prospective cohort study of aging and health in community-dwelling older adults in 
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Singapore. A whole population sample of participants was identified through door-to-
door census in five contiguous districts in the South, East and West Region of Singapore 
with over-representativeness of the Chinese population. The eligible population 
consisted of all older persons, Singaporean citizens or permanent residents, aged 55 and 
older, excluding individuals who were not able to participate because of severe physical 
or mental illnesses or incapacity. The response rate was 78%. The cohort members were 
first recruited in 2004/2005. The National University of Singapore institutional review 
board approved the study, and informed consents were obtained from all participants. 
A sub-group (N=2774) of SLAS cohort with inflammatory cytokine test results was 
selected from the main cohort for quality of life and inflammatory cytokine related 
studies. Compared to the non-participants, the sub-group participants did not differ on 
demographic variables, depressive symptoms and cancer prevalence rate at baseline 
assessment. Within this sample, 82 participants have self-reported a cancer history 
before recruitment.  
 
Baseline and Outcome Measurements: 
 
Data collected at baseline were potential confounders in analyses included age, 
gender, housing type (a validated surrogate measure of socioeconomic status among 
Singaporeans), ever smoking status, body mass index and medical comorbidities.      
 
Quality of life assessments 
Department of Psychological Medicine                                     Jiang Min-Jun, HT090037M 
31 
 
Quality of life assessments include mental / physical health functioning, life 
satisfaction and depressive symptoms. The mental / physical health status of the study 
participants was assessed using the Mental / Physical Component Summary (MCS) score 
of the 12-item Short-Form (SF-12) Health Survey for mental / physical health functioning, 
self-reported Life Satisfaction score (LS) for life satisfaction and the 15-item Geriatric 
Depression Scale (GDS) score for depressive symptoms. 
 
The 12-item Short-Form (SF-12) Health Survey, an abbreviated version of the full 
SF36 Health Survey, is widely used in research as a generic instrument to assess mental 
and physical health functioning across a wide range of medical conditions and health 
states. Response scores of the SF-12 are weighted and summed to provide easily 
interpretable scales for mental and physical health functioning. MCS and PCS are 
computed using the scores of twelve questions and range from 0 to 100, where a zero 
score indicates the lowest level of health and 100 indicates the highest possible level of 
health. Participants whose had their SF-12 MCS or PCS scores within the lowest tertile 
were considered to have poor mental or physical  health functioning, while participants 
whose had their SF-12 MCS or PCS scores above the lowest tertile were considered to 
have normal mental and physical health functioning.  
 
A self-reported life satisfaction score (LS) was determined by means of a scale 
with four questions.  It has been modified[105] from studies on quality of life conducted 
in the University of Michigan[106] and used across Nordic countries,[105] among the 
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general population[107] and psychiatric patients[108]. It defined as interest in life, 
happiness, loneliness, and general ease of living. The range of the sum score for life 
satisfaction was 4–20, with increasing values indicating a decrease in life satisfaction. 
 
Symptoms of depression were assessed using Geriatric Depression Scale (GDS) 
short form. It is a 15-question screening tool for depression in older adults taking five to 
seven minutes to complete. It consists of 15 questions requiring "yes" (1) or "no" (0) 
answers for depression assessment in older adults. The GDS has been validated in the 
local population as a screening instrument for depression [96]. A summed score equal to 
or greater than 5 is indicative of clinically significant depressive symptoms. 
 
Cytokines 
Inflammatory cytokines assessed concurrently with psychological assessments at 
baseline of this study included C-reactive protein (CRP), interleukin 6 (IL-6) and tumor 
necrosis factor-alpha (TNF-α).  
 
Serum concentrations of IL6, TNF- α and CRP were measured by quantitative 
enzyme-linked immune sorbent assay (ELISA) techniques based on appropriate and 
validated sets of monoclonal antibodies. TNFA and IL-6 were run on Immulite analyser 
from Siemens Healthcare. CRP was run using Calbiotech kits. All biological samples were 
assayed by personnel who were blind to the diagnostic identity of the study subjects. 
 





All statistical analyses were performed using SPSS 17.0 statistical software (SPSS 
Inc., Chicago, IL). Between-group differences for continuous variables were tested by 
one-way analyses of variance (ANOVAs), independent sample t-test and differences in 
categorical variables were tested using χ2 analyses. An adjusted P value of less than .05 
was considered significant. Univariate analyses of covariance (ANCOVAs) adjusting for 
age were performed to test whether CRP, IL-6, and TNF-α levels differed between four 
groups. Post hoc tests comparing each pair of groups were conducted after significant 
ANCOVAs. All ANCOVA models used two-sided tests of significance with Bonferroni-
adjusted P values. 
 
3.4 Study IV: Response Shift Phenomena 
 
Study Participants and Procedures  
 
Breast cancer is the most common female cancer in Singapore. Almost 90% of 
breast cancer patients can survive more than 5 years. For the specific purpose of the 
current study, patients who were newly diagnosed with breast cancer were recruited 
upon fulfilling the exclusion and inclusion criteria. 
Inclusion Criteria 
(1) Female patients 
(2) Newly diagnosed localized breast cancer 
(3) English or Mandarin speaking  
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(4) Age 21 and 65 
(5) Able to give written informed consent. 
(6)        Need to do chemotherapy  
            
Exclusion Criteria  
(1) Metastases including regional lymph node spread 
(2) Past or concurrent psychiatric disorders (major depression, psychosis, etc) 
(3) Past or concurrent major medical disorders with severe psycho-social and quality 
of life impairments, such as systemic lupus, rheumatoid arthritis, other auto-immune 
disorders, stroke, neurological disorders, hormonal and endocrine disorders, e.g. thyroid, 
etc. 
(4) Pregnancy  
(5) Prior receipt of psychological or counseling services for psychological and 
emotional problems from existing service providers 
 
After the participants had given their written informed consent, they filled out the 
Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) questionnaire twice. 
The first time was with regards to their current level of QOL, and the second time was 
on their perception of their QOL previously. The second time questionnaire constituted 
the Then Test, which was implemented to the FACT-B. Following which, the participants 
participated in the Card Sort Game (also adapted to FACT-B). The rest of the 
questionnaire included demographic and personal variables such as name, age, 
identification number and contact details. Participants had audio-taped interviews after 
completion of each of the assessment tools, in order to capture any comments with 
regards to any difficulties encountered while completing the assessments. 




Following the first assessment, which took place at subject recruitment, the same 
participants were similarly re-assessed when they were to go for surgery and 
chemotherapy. The treatment plan and schedule for each patient was sought from the 




The instructions of all assessment used were given to the patients in both 
written and verbal form each time they were being assessed. The recruited patients 
were repeatedly assessed at various stages: 
I) Assessment began with the diagnosis stage whereby they had just been 
diagnosed with breast cancer, and had yet to receive neither surgery nor 
therapy. 
II) The next point of assessment was the surgical stage whereby patients who 
underwent surgery were assessed shortly (within 2 weeks) after they had the 
operation, and before they received chemotherapy. The type of surgery 
(lumpectomy vs. mastectomy) was taken note of as there might be a 
difference in the psycho-social impact caused by the two different surgical 
procedures.  
III) The third stage was when the patient received adjuvant chemotherapy. 
Assessment took place at about the sixth week of the chemotherapy. 
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The Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B)[109, 110]  
comprises a General version (FACT-G) of the cancer-specific QOL measure, plus an 
additional subscale of breast cancer specific concerns (AC). FACT-G itself is a widely used 
QOL instrument, which comprises 27 questions that assesses four domains of QOL, 
namely the physical well-being (PWB, 7 items), social and family well-being (SWB, 7 
items), emotional well-being (EWB, 6 items) and functional well-being (FWB, 7 items). 
The questionnaire uses the 5-point Likert scale type of response categories (0 = Not at 
all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). FACT-B includes 
the core FACT-G questionnaire as well as the breast cancer specific subscale which “is 
intended to be as specific as necessary to capture the clinically-relevant problems” 
(Functional Assessment of Chronic Illness Therapy official website) associated with 
breast cancer. FACT-B is chosen as this study only examines issues related to breast 
cancer patients. 
 
The Then Test approach[111] is used to reflect change in internal standards 
(recalibration) and reconceptualisations giving rise to response shift. It can be 
implemented on QOL tools such as FACT-B. This approach not only uses an individual’s 
response to the first evaluation and second evaluation, but also uses a then measure, 
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which is a retrospective rating of the first evaluation. The then measure is completed at 
the same time as the second evaluation, and requires subjects to complete the self-
report measure in reference to how they perceive themselves to have been at the first 
evaluation. Then Test approach has been used and proved effective in various studies 
on different groups of patients.[112, 113] 
 
The Card Sort Game[114] is used to reflect changes in values and 
reconceptualisations giving rise to response shift. It is an adapted game whereby the 
participants are required to place cards on a sorting sheet to describe the relative 
importance of the quality of life variables listed in each of the sub-scales in FACT-B. It 
allows the ranking of importance of the quality of life variables within the sub-scales, as 
well as the ranking of importance of the sub-scales themselves. Each patient will be 
given the Card Sort Game package. The package includes four sets of card sort sheets 
and cards for the FACT-B sub-group variables, and one set of card sort sheet and cards 
for the sub-groups themselves. This approach is similar to a Q-Sort methodology[115, 
116]which attempted to allow investigators to examine correlations between different 
conditions for the same person. Like the pairwise comparison technique, the Card Sort 
approach might be used to assess changes in values. If patients can choose their own 
domains, then this method can reflect reconceptualisation. The card sort method has a 
well-established foundation in ipsative measurement.[113] Additionally, a recent 
investigation of a card sort method to evaluate coping variability with life stressors 
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In order to detect a difference of 1 SD in mean QOL values between baseline and 
subsequent assessments, a sample size of 30 patients is required (90% power and 5% 
alpha). A difference of 1 SD is considered a small-to-moderate effect size[118] and is a 
clinically significant difference of QOL[119].  The sample size estimation takes into 
account repeated assessments and incomplete data, as it is estimated that proportion 
of cases who do not need chemotherapy after surgery is around 10 to 15%. This is 
assuming that the correlation between assessments is 0.2 and that the percentages of 
patients who completed 4, 3, 2 and fewer than two assessments are 75%, 15%, 10% and 
0% respectively[120]. 
 
Maximum likelihood estimation using all available data[120] was employed to 
analyze the means of changes in QOL scores from baseline to the treatment phase. The 
Holm’s method was used to adjust the P-values, which were affected by the inflation of 
type I error due to multiple testing of various QOL scores[121].  
 
The presence of response shift using the Then Test approach was documented 
and described by examining the differences in scores of the pre-test and then-test 
scores of the Then Test, at each of the four assessment stages, using paired t-tests.  
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Differences in rank order values reflecting relative importance of domains in the 
FACT-B were compared between those at baseline and each subsequent re-assessment 
stage, using Friedman tests. 
 
Differences in reconceptualization of QOL between baseline and at each re-
assessment were assessed qualitatively from verbal and/or written responses. 
 
CHAPTER 4: RESULTS 
 
4.1 Study I: Psychological Status and Cancer Incidence 
 
The mean (SD) follow up period for the 2620 cancer-free subjects in the cohort 
was 71.3 (12.6) months, during which a total of 179 (6.8%) cases of all-sites cancers 
were confirmed based on ICD-9 classification criteria by Singapore National Disease 
Registry Office.  Overall, the mean (SD) SF12-MCS score was 53.8 (8.2), SF12-PCS score 
was 48.4 (7.5), and GDS score was 1.9 (2.7). Participants whose SF-12 MCS / PCS score 
fell into the lowest tertile were classified as having poor mental / physical health 
functioning (N=872, 33.3%). Approximately 13.1% (N=343) had GDS ≥5 indicating 
depressive symptoms, and only less than 4% had GDS ≥10 indicating depression. 
 
Characteristics of Participants by Mental and Physical Health Functioning 
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Participants with poor mental health functioning, compared with their normal 
counterparts, were significantly (P<0.05) older, had greater proportions who were of 
non-Chinese ethnicity, living in lower-end public (1-3 rooms) housing, divorced, 
widowed, or single, had significantly more medical co-morbidities, and lower mean SF-
12 PCS scores (Table 1). There was a very weak correlation between SF-12 MCS score 
and PCS score, r=.114 (p<.001). Notably, participants with poor mental health 
functioning had significantly higher mean GDS score (p<0.001) with higher proportions 
with depressive symptoms (28.5% versus 5.4%, P<0.001).  There was a moderate 
correlation between SF-12 MCS with GDS score,  r=-.398 (p<.001).  
 
Participants with poor physical health functioning, compared with their normal 
counterparts, were also significantly (p<.05) older, had significantly greater proportions 
living in lower-end public (1-3 rooms) housing, divorced, widowed, or single, and 
showed higher mean GDS score. There was a weak-to-moderate correlation between 
SF-12 PCS with GDS score, r=-.333 (p<.001). However, poor physical functioning was 
significantly associated with being female, overweight or obese, and multiple medical 
comorbidity (p<0.001).  
 
Participants with depressive symptoms (GDS ≥ 5) compared with non-depressed 
participants had significantly (p<.05) greater proportions of those were living in lower-
end public (1-3 rooms) housing, divorced, widowed, or single, had more medical co-
morbidities, and lower mean scores of SF-12 MCS and PCS.  




There were significantly more incident cancer cases among participants with 
poor mental health functioning (73/872, 8.4%) than their normal counterparts 
(106/1748, 6.1%). No significantly increased incidence of cancer was found for 
participants with poor physical health functioning or depressive symptoms (Table 1). 
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Table 1. Baseline Characteristics of Participants by Mental and Physical Health Functioning and GDS status* (SF-12 MCS and PCS†) 
 


















             
Age, y Mean (SD) 66.4(7.84) 65.7(7.48) 0.038  68.1(8.68) 64.8(6.75) <0.001  65.8(7.45) 0.105 0.105 
 ≥70 years 254(29.1%) 458(26.2%) 0.113  345(39.6%) 367(21.0%) <0.001  108(31.5%) 604(26.5%) 0.055 
             
Sex Female 553(63.4%) 1096(62.7%) 0.720  595(68.2%) 1054(60.3%) <0.001  219(63.8%) 1429(62.8%) 0.711 
             
Ethnicity Chinese 797(91.4%) 1642(93.9%) 0.016  807(92.5%) 1632(93.4%) 0.437  323(94.2%) 2114(92.9%) 0.396 
             
Housing Public 1-3 room size housing 298(34.2%) 486(27.8%) 0.001  284(32.6%) 500(28.6%) 0.037  145(42.3%) 638(28.0%) <0.001 
             
Marital Single, divorced, widowed 256(29.4%) 437(25.0%) 0.017  288(33.0%) 405(23.2%) <0.001  118(34.4%) 574(25.2%) <0.001 
             
BMI, kg/m2 Mean (SD) 23.7(3.97) 23.8(3.69) 0.341  24.1(3.99) 23.6(3.67) 0.002  23.6(4.17) 23.8(3.73) 0.415 
 ≥ 23 kg/m2 481(55.2%) 978(56.1%) 0.679  512(59.0%) 947(54.2%) 0.020  173(50.7%) 1285(56.6%) 0.043 
             
Ever smoker Yes 51(7.5%) 89(7.5%) 0.976  41(6.2%) 99(8.2%) 0.106  27(9.2%) 113(7.2%) 0.236 
             
Medical comorbidities Mean (SD) 2.4(1.46) 2.3(1.44) 0.002  2.8(1.56) 2.1(1.34) <0.001  2.6(1.53) 2.3(1.44) <0.001 
 ≥3 43(4.9%) 83(4.7%) 0.837  68(7.8%) 58(3.3%) <0.001  317(92.4%) 2175(95.6%) 0.010 
             
SF-12 PCS Mean (SD) 46.9(8.81) 49.1(6.58) <0.001  - - -  43.3(9.58) 49.1(6.75) <0.001 
 Poor† physical health funcZon 375(43.0%) 497(28.4%) <0.001  - - -  199(58.0%) 671(29.5%) <0.001 
             
SF12-MCS Mean (SD) - - -  52.3(9.94) 54.5(7.05) <0.001  44.9(10.35) 55.1(6.89) <0.001 
 Poor† mental health funcZon - - -  375(43.0%) 497(28.4%) <0.001  248(72.3%) 623(27.4%) <0.001 
             
GDS Mean (SD) 3.4(3.56) 1.1(1.78) <0.001  2.9(3.24) 1.4(2.28) <0.001  - - - 
 ≥5 248(28.5%) 95(5.4%) <0.001  199(22.9%) 144(8.2%) <0.001  - - - 
             
Cancer Yes 73(8.4%) 106(6.1%) 0.027  59(6.8%) 120(6.9%) 0.925  22(6.4%) 157(6.9%) 0.739 
Figures shown are n (%) and mean (SD) 
Abbreviations: BMI, body mass index; SF12-MCS, 12-item health survey-mental health component score; SF12-PCS, 12-item health survey-physical health component score; GDS, geriatric depression scale. 
*Data are presented as percentage of participants unless otherwise indicated. One-way analysis of variance, independent, 2-tailed t test was used for continuous variables (to determine the mean), and the χ² 
test was used for categorical variables (to determine the percentage). 
†SF12 Mental Health Composite Scores (MCS) and Physical Health Composite (PCS) range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the 
highest level of health. Poor indicates a person’s score was in the lowest tertile. GDS range from 0 to 15, higher score indicates more depressive symptoms. 
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Poor Mental Health Status and Cancer Incidence 
Figure 1, 2 and 3 show Kaplan-Meier cumulative hazard estimates of cancer 
incidence by mental health status (SF12-MCS), physical health status (SF12-PCS), and 
depressive symptoms (GDS≥5). Participants with poor mental health showed a 
statistically significant increased risk of developing cancer during the 6 years of follow-
up (unadjusted hazard ratio=1.35, p=.049). On the other hand, participants with poor 
physical health status did not show an increased risk (unadjusted hazard ratio=0.95, 
p=0.77). No statistically significant increased risk of cancer was observed for participants 
with depressive symptoms (unadjusted hazard ratio=0.41, p=0.525).  
 
 
Figure 1. Kaplan-Meier Cumulative Hazard Estimates of Cancer Incidence by Mental 
Health Status (SF12-MCS).  
 
 























Figure 2. Kaplan-Meier Cumulative Hazard Estimates of Cancer Incidence by Physical 

























Hierarchical models considering potential confounding by cancer risk factors 
showed that poor mental health remained significantly associated with incident cancer 
risk after controlling for demographic factors and smoking history (HR=1.42, 95% 
CI=1.02-1.97, p=.039), and medical comorbidity and BMI (HR=1.42, 95% CI=1.02-1.98, 
p=.038).  
 
Table 2. Hierarchical Cox Regression Analyses: Association of poor mental health 
with cancer incidence adjusted for confounding risk factors 
 Variable HR 95% CI 
P 
value 
     
Model 1 Unadjusted 1.35 1.00-1.82 0.049 
     
Model 2 
Adjusted for age, gender, housing status, 
smoking 
1.42 1.02-1.97 0.039 
     
Model 3 
Adjusted for age, gender, housing status, 
smoking, comorbidity and BMI 
1.42 1.02-1.98 0.038 
     
Poor self-reported mental health: lowest tertile of SF-12 MCS  
 
In stratified analyses, we explored the prognostic association of SF-12 MCS with 
cancer risk in relevant population subgroups. Although tests of interaction effects were 
not statistically significant, elevated risks of overall cancer associated with poor mental 
health status were suspected among participants who were male (adjusted HR=1.68, 95% 
CI= 1.06-2.65, p=.027), living in lower-end public housing (adjusted HR=1.60, 95% 
CI=1.06-2.39, p=.024) and those with less than 3 comorbidities (adjusted HR=1.44, 95% 
CI=1.03-2.02, p=.033).  (Table 3)  
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Table 3. of Association between low mental health functioning and cancer incidence 
(95% CI) in stratified Cox regression analysis  
 Adjusted HR (95% CI) P value 
P value 
(interaction) 
Age    
        < 70 1.51(0.99-2.31) 0.055 
0.53 
        ≥ 70 1.30(0.77-2.21) 0.33 
Gender    
        Male 1.68(1.06-2.65) 0.027 
0.30 
        Female 1.19(0.74-1.92) 0.47 
Housing Type    
        1-3 room HDB 1.60(1.06-2.39) 0.024  
0.32         ≥ 4 room HDB or private 
property 
1.13(0.64-1.99) 0.67 
BMI    
        < 23 1.39(0.83-2.31) 0.21 
0.88 
        ≥ 23 1.43(0.93-2.21) 0.104 
Smoking    
        Yes 2.44(0.83-7.12) 0.103 
0.34 
        No 1.33(0.94-1.88) 0.112 
Comorbidity    
        ≥ 3 






Age, Gender, Housing type, BMI, Smoking-adjusted Hazard Ratios 
 
As poor mental health functioning could possibly accompany early unrecognized 
stage of cancer development, we repeated the analyses of poor mental health status in 
predicting cancer risk by excluding subjects with incident cancer occurring within 1 years 
after the baseline. We observed similar cancer incident risk in participants with poor 
mental health compare with their normal counterparts (HR=1.38, 95% CI=0.97-1.97, 
p=.075), controlling for demographic factors, smoking history, medical comorbidity and 
BMI.   
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We further investigated site-specific cancers for female breast cancer and male 
lung cancer, which are hormone-related and tobacco-related cancer that have been 
shown in a few previous studies to be likely linked to depression.  We found that poor 
mental health status was significantly associated with elevated breast cancer incidence 
(HR=2.96, 95%CI: 1.07-8.16, p=.036) and male lung cancer incidence (HR= 3.45, 95%CI: 
1.03-11.51, p=.044), controlling for demographic factors, smoking history, medical 
comorbidity and BMI.    
 
Relations among psychological variables 
Table 4 presented the correlations among psychological variables of interest (SF-
12 MCS, SF-12 PCS and GDS). SF-12 MCS score showed very weak positive correlation 
with SF-12 PCS score(r=.114, p<.001). SF-12 MCS and SF-12 PCS showed moderate 
negative correlation with GDS total score(r=-.398 p<.001; r=-.333, p<.001).  
 
Table 4. Correlations among SF-12 MCS, SF-12 PCS and GDS 
 SF-12 MCS SF-12 PCS GDS 
SF-12 MCS -   
SF-12 PCS .114** -  
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4.2 Study II: Depression and Mortality in Cancer Survivors 
 
Prevalence of Depression  
In the total cohort (N=1092), the prevalence of depression overall was 14.5% (threshold, 
3.7% and sub-threshold, 10.8%). Among the 61 participants who had had a diagnosis of 
cancer, the prevalence of depression overall at 23.0% (threshold 6.7% and sub-threshold 
depression 16.4%) was about twice higher than the prevalence of depression at 14.0% 
(threshold, 3.5% and sub-threshold, 10.5%) among non-cancer participants.  
 
Characteristics of Cancer Participants by Depression Diagnosis 
As shown in Table 5, the average survival time in cancer patients with depression was 
14.4 (9.07) years before date of interview (DOI) since cancer diagnosis, while 10.4 (8.91) 
years in patients without depression. No statistically significant differences were found 
between participants with / without depression on survival time before DOI and total 
survival time since cancer diagnosis. Compared to their counterparts without depression, 
cancer survivors with depression were more likely to have worse social economic status, 
more medical comorbidities, poorer physical functioning, and shorter survival time from 
date of interview. 
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Age, y Mean (SD) 72.9 (6.89) 71.9 (8.15) 0.668 
 ≥70 years 9 (64.3%) 27 (57.4%) 0.648 
     
Sex Female 8 (57.1%) 25 (53.2%) 0.795 
     
Ethnicity Chinese 6 (42.9%) 27 (57.4%) 0.336 
     
Housing status Public 1-2 room size 3 (21.4%) 1 (2.1%) 
0.008 
 Public 3-4 room size 11 (78.6%) 34 (72.3%) 
 Public 5 room or 
higher 
0 (0.0%) 12 (25.5%) 
     
Marital Single, divorced, 
widowed 
4 (34.0%) 16 (28.6%) 0.702 
     
Ever smoker Yes 3 (21.4%) 2 (4.3%) 0.004 
     
Medical comorbidities Mean (SD) 3.9 (2.56) 2.0 (1.58) 0.016 
 ≥2 10 (71.4%) 28 (59.6%) 0.422 
     
Survival before DOI since cancer 
diagnosis, y 
Mean (SD) 14.4 (9.07) 10.4 (8.91) 0.145 
     
Total Cancer Survival, y  Mean (SD) 19.7 (9.36) 18.3 (10.73) 0.665 
     
Survival from DOI, y Mean (SD) 5.3 (3.18) 7.9 (3.32) 0.011 
     
Figures shown are n (%) and mean (SD) 
Abbreviations: DOI; date of interview. 
*Data are presented as percentage of participants unless otherwise indicated. One-way 
analysis of variance, independent, 2-tailed t test was used for continuous variables (to 
determine the mean), and the χ² test was used for categorical variables (to determine the 
percentage). 
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The cancer survivors presented with 21 different malignant neoplasms. The 
largest majority was breast cancer among females (14.8%, n=9) and prostate cancer 
among males (11.5%, n=7). At the end of the follow up, nearly half of them (28/61) had 
died, 14 of them from cancer (9 from the primary cancer, and 5 from a second cancer), 
and the rest from non-cancer causes (4 from stroke, 3 from heart disease, 3 from 
pneumonia, and 3 from other causes).   
 
Overall, the mean (SD) age of the 61 cancer survivors was 72.1 (7.8) years. At 
survey interview, the mean survival duration since first diagnosis of cancer was 11.3 
(9.03) years. The mean (SD) total cancer survival duration was 18.6 (10.38) years. The 
mean (SD) follow up period was 7.7 (0.45) years.  
 
Depression and Mortality among cancer participants 
By December 31
st
 2012, all cancer survivors with threshold depression were deceased, 
with mean (SD) survival of 5.6 (1.69) years; 70.0% of cancer survivors with sub-threshold 
depression were deceased, with mean (SD) survival of 5.3 (1.01) years. (Figure 4 & 5) In 
total, among cancer survivors with depression overall, 78.6% were deceased, with mean 
(SD) survival of 5.3 (0.88) years. At the same time, only 37.0% of cancer survivors 
without depression were deceased, with mean (SD) survival of 8.4 (0.48) years. (Table 6) 
 




Figure 4 Kaplan-Meier survival estimate in Cancer Survivors with depression (threshold + 












Figure 5 Kaplan-Meier survival estimate in Cancer Survivors with threshold, sub-
threshold depression and non-depression.  
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Table 6. Mortality of cancer survivors followed up over 8 years 
    Survival (years) 
Depression status Total N Dead N Percentage Mean SD 
Threshold/Sub-threshold 14 11 78.6% 5.3 0.88 
Threshold 4 4 100.0% 5.6 1.69 
Sub-threshold 10 7 70.0% 5.3 1.01 
No depression 47 17 37.0% 8.4 0.48 
Overall 61 28 46.7% 7.7 0.45 
 
Cancer survivors with depression overall showed a statistically significant 
increased mortality risk during the 8 years of follow-up (unadjusted hazard ratio=3.42, 
p=.002). (Table 7) Adjusted for age, sex, housing status, smoking history and medical 
comorbidities, the mortality risk associated with depression remained significantly 
increased (adjusted HR=2.38, 95%CI: 1.03-5.46, p=0.041) (Table 7). The difference in 
survival between participants with threshold and sub-threshold depression was not 
statistically significant. (Figure 5) Although test of interaction was not statistically 
significant, stratified analyses by sex suggested the potential association of threshold 
depression with mortality hazard was higher in men than women. (Table 8) 
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Table 7. Association of depression (threshold and sub-threshold) with cancer survival adjusted for confounding risk factors in 
hierarchical Cox regression analyses 
 
  Depression  Sub-threshold Depression  Threshold Depression 
 Variable HR 95% CI p  HR 95% CI p  HR 95% CI p 
Model 1 Unadjusted 3.42 1.57-7.45 0.002  3.10 1.26-7.64 0.014  4.15 1.38-12.47 0.011 
Model 2 Adjusted for age, gender 3.49 1.59-7.65 0.002  3.22 1.31-7.95 0.011  3.57 1.17-10.91 0.026 
Model 3 Adjusted for age, gender, 
housing status, smoking and 
medical comorbidity 
2.38 1.03-5.46 0.041  2.89 1.08-7.90 0.034  1.73 0.49-6.15 0.399 
 
 
Table 8. Stratified analysis of association of depression (sub-threshold and threshold) with cancer survival by gender 
 
 Depression  Sub-threshold Depression  Threshold Depression 
 Adj HR 95% CI p  Adj HR 95% CI p  Adj HR 95% CI p 
Men 2.37 0.52-10.90 0.267  2.37 0.52-10.90 0.267  11.14 0.89-138.81 0.061 
Women 2.44 0.82-7.33 0.109  3.11 0.70-13.71 0.135  1.78 0.30-10.53 0.521 
Adj HR: Hazard risk adjusted for age, housing status, smoking and medical comorbidity 





Depression and Mortality in long-term cancer survivors 
We defined a subgroup of long-term cancer survivors (N=52) by excluding 9 cancer 
survivors who died within 5 years from their dates of first diagnosis. Among them, 
participants with depression showed substantially higher mortality risk (adjusted 
HR=4.69, 95%CI: 1.76-12.47, p=0.002) comparing to their counterparts after adjusting 
demographic characteristics, social economic status, smoking history and medical 
comorbidities.  
 
Depression and Mortality in female breast cancer survivors 
We further explored site-specific cancers for female breast cancer (N=9), which are 
hormone-related cancer that have been shown in a few previous studies to be likely 
linked to depression. Depression was associated with increased mortality in female 
breast cancer survivors (HR=11.6, 95%CI: 0.69-194.1, p=0.089), controlling for 
demographic factors, social economic condition, smoking history and medical 
comorbidity), although not statistically significant at p<0.05, given the small sample size.  
 
Self-reported Health Status and Cancer Mortality 
The overall mean (SD) SF-12 PCS score was 45.0 (10.23), and SF-12 MCS score was 50.6 
(8.36). By December 31
st
 2012, 68.4% cancer survivors with poor physical health status 
deceased with a mean (SD) survival of 6.0 (0.78) years in 8 years follow-up, compare to 
their counterparts with 35.0% mortality and a mean (SD) survival of 8.7 (0.48) years. 
52.6% cancer survivors with poor mental health status deceased with a mean (SD) 
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survival of 7.1 (0.78) years in 8 years follow-up, compare to their counterparts with 42.5% 
mortality and a mean (SD) survival of 8.1 (0.52) years.  
 
Figure 6 & 7 represent Kaplan-Meier survival curve estimation of cancer mortality 
stratified physical / mental health status (SF12-PCS/MCS). Cancer survivors with poor 
physical health functioning demonstrated an increased mortality risk (unadjusted hazard 
ratio=2.98, 95%CI: 1.38-6.43, p=0.005) compare to their counterparts. Cancer survivors 
with poor mental health functioning, however, demonstrated the similar tendency but 
not a statistically increased mortality risk (unadjusted hazard ratio=1.34, 95%CI: 0.61-
2.93, p=0.464) compare to their counterparts.  
  
Figure 6. Kaplan-Meier Survival estimate in cancer Survivors by physical health 
functioning (SF12-PCS). 














Figure 7. Kaplan-Meier Survival estimate in cancer Survivors by mental health 
functioning (SF12-MCS). 
 
After adjusting for demographic factors, social economic condition, smoking 
history and medical comorbidities, cancer survivors with poor physical health status 
demonstrated an increased mortality risk (adjusted hazard ratio=2.59, 95%CI: 1.10-6.08, 
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4.3 Study III: Quality of Life in Long-term Cancer Survivors 
 
Characteristics of Participants 
A subgroup of 2774 elderly subjects were selected from SLAS main cohort with mean 
(SD) age of 66.3 (7.8) years, which did not differ from the rest of main cohort on 
demographic characteristics.  31.3% (N=869) participants were aged 70 and above. 62.9% 
(N=1745) participants were female. 90.1% (N=2499) participants were Chinese. 3.0% 
(N=82) participants had cancer history.  
 
Association of QOL with cancer history 
Cancer survivors, compared with those non-cancer elderly in this community sample, 
showed no statistically significant differences in age, gender, ethnicity, housing 
condition, marital status, smoking history, medical comorbidities and BMI.  
 
Also, no statistically significant difference were found in SF-12 physical and 
psychological domains (SF-12 PCS and SF-12 MCS), life satisfaction level (LS) and 
depression level (GDS) (p > 0.05). (Table 9) There is no change of the association 
between cancer history and QOL, life satisfaction level and depression level after 
adjusting for age, gender, ethnicity, housing condition, marital status, smoking history, 


















     
Age, y Mean (SD) 67.5(8.3) 66.2(7.8) 0.161 
 ≥70 years 26(31.3%) 843(31.7%) 0.940 
     
Gender Female 59(72%) 1686(62.6%) 0.085 
     
Ethnicity Chinese 76(92.7%) 2423(90.1%) 0.678 
     
Housing status Public 1-2 room size 18(22.0%) 418(15.6%) 0.561 
     
Marital status Single, divorced, 
widowed 
33(40.2%) 883(32.8%) 0.561 
     
Ever smoker Yes 7(10.8%) 226(10.6%) 0.959 
     
Medical comorbidities Mean (SD) 0.3(0.5) 0.3(0.5) 0.899 
     
BMI Mean(SD) 24.0(3.5) 24.0(4.0) 0.890 
     
SF-12 PCS Mean (SD) 48.7(6.3) 49.0(6.8) 0.697 
     
SF-12 MCS Mean (SD) 54.5(6.8) 55.1(7.5) 0.484 
     
LS Mean (SD) 7.6(2.7) 7.7(2.3) 0.699 
     
GDS Mean (SD) 1.1(2.2) 1.0(1.9) 0.787 
     
Figures shown are n (%) and mean (SD) 
*Data are presented as percentage of participants unless otherwise indicated. One-way 
analysis of variance, independent, 2-tailed t test was used for continuous variables (to 
determine the mean), and the χ² test was used for categorical variables (to determine the 
percentage). 
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4.4 Study IV: Response Shift Phenomena in Breast Cancer Patients 
 
Characteristics of Participants 
34 female who were suspected localized breast cancer were recruited with 
consent form obtained before their surgical operations. After surgery and pathological 
examination, 17 patients were excluded from the study because chemotherapy was not 
necessary or refused and 2 patients dropped out during follow-up. Finally 15 patients 
finished four assessments during one year follow-up. The mean (SD) age of participants 
was 49.6 (8.7) years with range from 31 to 64 years. 80% of participants were married 
while the rest three were single, divorced or widowed. All the participants received at 
least primary education, and 53.3% of them finished university or higher education. 
 
Quality of Life 
(1) Changes on Current QOL Scores of FACT-B 
Table 10 and Figure 8 showed current QOL scores (total score and domain scores 
using FACT-B) amongst four assessments during one year follow-up in breast cancer 
patients. The difference in total QOL score between assessments was statistically 
significant (p<0.01). Except Social/Family Well-being domain, statistically significant 
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1 2 3 4 
Physical Well-being 25.20  21.13  20.60  25.40  0.002 
Social/Family Well-being 21.67  23.33  20.93  21.80  0.517 
Emotional Well-being 17.27  19.73  19.60  22.60  <.0001 
Functional Well-being 19.93  16.00  17.93  23.47  0.001 
Additional Concerns 23.67  22.20  24.13  28.27  <.017 
Total Score 107.74  102.39  103.19  121.54  <.0001 
Note: 1. Assessment 1: Before surgery 
               Assessment 2: 2 weeks after surgery 
               Assessment 3: During chemotherapy 
               Assessment 4: 1 year after surgery 
           2. Figures in cell are the current QOL scores. 
 
 
Figure 8. Current QOL scores (FACT-B) amongst four assessments in breast cancer 
patients 
 
Similar with total QOL score, functional well-being domain declined dramatically 
and touched their bottoms after surgical operations, partially recovered during 
chemotherapy period and fully recovered after 1 year. Physical well-being domain, 
however, kept declining and touched bottom during chemotherapy and fully recovered 
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after 1 year. On the other hand, emotional well-being started from its lowest level and 
kept climbing during one year follow up. Additional concern domain remained stable 
during the first six months, but increased sharply after one year. 
 
(2) Changes on Then-Test QOL Scores of FACT-B  
 
Table 11 and Figure 9 showed Then-Test QOL scores (total score and domain 
scores using FACT-B) amongst four assessments in breast cancer patients. The difference 
in total QOL score and all domains between assessments was statistically significant 
(p<0.01). During the first six months of disease treatment journey, PWB, FWB and AC 
domains kept declining from their QOL before cancer. EWB domain remained stable 
before declining due to harmful effect caused by chemotherapy. SWB, on the contrary, 
kept increasing steadily during first six months of cancer diagnosis and treatment 
journey. 
 





1T[0] 2T[1] 3T[2] 4T[3] 
Physical Well-being 27.33  25.47  22.93  13.00  <.0001 
Social/Family Well-being 11.93  18.80  18.87  20.07  <.0001 
Emotional Well-being 19.27  17.00  19.20  15.73  <.0001 
Functional Well-being 20.67  18.60  18.20  16.00  0.001 
Additional Concerns 30.60  24.20  23.67  20.20  <.0001 
Total Score 109.80  104.07  102.87  85.00  <.0001 
Note: 1. Assessment 1T [Assessment 0]: Pre-diagnosis 
               Assessment 2T [Assessment 1]: Before Surgery 
               Assessment 3T [Assessment 2]: 2 weeks after surgery 
               Assessment 4T [Assessment 3]: During chemotherapy 
           2. Figures in cell are the Then-Test QOL scores. 
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(1) Change in Internal Standard (Recalibration) 
Comparing current and Then-test QOL total scores of FACT-B, statistically 
significant difference was only shown during chemotherapy period (p<0.05). Then-test 
QOL score was significantly lower than current QOL score, indicating worse QOL level. 
No difference was found in QOL total score of FACT-B at other assessment points (Table 
12 and Figure 10).  
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Table 12. Difference between current and Then-test FACT-B total scores amongst 
assessments in breast cancer patients.  
FACT-B 
Assessments 
0 1 2 3 4 
Then Score 109.80 104.07 102.40 85.00  
Current Score  107.73 102.87 103.20 121.54 
P value  0.545 0.941 0.013  
Note: Assessment 0: Before diagnosis 
           Assessment 1: Before surgery 
           Assessment 2: 2 weeks after surgery 
           Assessment 3: During chemotherapy 
           Assessment 4: 1 year after surgery 
 
 
Figure 10. Difference between current-test and then-test FACT-B total scores amongst 
assessments in breast cancer patients. 
 
3/5 domains of QOL, including PWB, EWB and AC, showed statistically significant 
difference between current and Then-Test QOL scores during period of chemotherapy. 
SWB domain showed statistically significant difference between current and Then-Test 
QOL score in the period of post-operation. No difference was found in FWB domain of 
QOL scores at all the assessment points. (Table 13-17 and Figure 11-15) 
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Table 13. Difference between current and Then- 





0 1 2 3 4 
Then 
Score 
27.33 25.47 22.93 13.00  
Current 
Score 
 25.20 21.13 20.60 25.40 
Figure 11. Difference between 
current and Then-Test PWB scores 
amongst assessments in breast  
cancer patients 





Table 14. Difference between current and Then- 





0 1 2 3 4 
Then 
Score 
11.93 18.80 18.87 20.07  
Current 
Score 
 21.67 23.33 20.93 21.80 
Figure 12. Difference between 
current and Then-Test SWB scores 
amongst assessments in breast  
cancer patients 





Table 15. Difference between current and Then- 





0 1 2 3 4 
Then 
Score 
19.27 17.00 19.20 15.73  
Current 
Score 
 17.27 19.73 19.60 22.60 
Figure 13. Difference between 
current and Then-Test EWB scores 
amongst assessments in breast  
cancer patients 
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Table 16. Difference between current and Then- 





0 1 2 3 4 
Then 
Score 
20.67 18.60 18.20 16.00  
Current 
Score 
 19.93 16.00 17.93 23.47 
Figure 14. Difference between 
current and Then-Test FWB scores 
amongst assessments in breast  
cancer patients 





Table 17. Difference between current and Then- 





0 1 2 3 4 
Then 
Score 
30.60 24.20 23.67 20.20  
Current 
Score 
 23.67 22.2 24.13 28.27 
Figure 15. Difference between 
current and Then-Test AC scores 
amongst assessments in breast  
cancer patients 
P value  0.8 0.454 0.014  
 
 
(2) Change in Values (Repriorization) 
Importance of domains Change at Assessment Intervals 
Application of Friedman's test showed that there were statistically significant 
changes in the importance of PWB(χ2(3, N=15)=15.19, p=0.002), EWB(χ2(3, 
N=15)=11.88, p=0.008) and FWB(χ2(3, N=15)=12.68, p=0.005) domains over the four 
assessments (Table 18 and Figure 16). No statistical significance was shown in SWB and 









































Table 18. Median Importance of domains at four assessments using FACT-B 
Median Importance of domains at Assessment Intervals 
 1 2 3 4 P-value 
Physical Well-being 3.29 3.57 3.57 1.86 0.002 
Social/Family Well-being 5.43 5.71 5.71 5.43 0.916 
Emotional Well-being 4.00 2.83 3.67 2.50 0.008 
Functional Well-being 5.57 5.0 5.57 6.14 0.005 
Additional Concerns 3.56 3.88 3.33 3.00 0.061 
Note: 1: Assessment 1: Before surgery 
           Assessment 2: 2 weeks after surgery 
           Assessment 3: During chemotherapy 
           Assessment 4: 1 year after surgery 
            2. Figures in cell are median importance score of FACT-B domains. 




Figure 16. Median Importance of domains at four assessments using FACT-B 
 
 
A pair-wise application of the Wilcoxon test with Bonferonni corrected levels of 
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significantly lower than that at assessment 1(p = 0.015), assessment 2(p=0.015) and 
assessment 3(p=0.006). (Table 19) 
 






























.944 .157 .002 .055 .005 .005 
Note: a. Based on negative ranks. 
           b. Based on positive ranks. 
 
 
 A pair-wise application of the Wilcoxon test with Bonferonni corrected levels of 
observed significance showed that importance of EWB domain at assessment 4 was 
significantly lower than that at assessment 1(p = 0.015), and assessment 3(p=0.048). 
(Table 20) 
 






























.098 .036 .016 .695 .005 .106 
Note: a. Based on positive ranks. 
           b. Based on negative ranks. 
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A pair-wise application of the Wilcoxon test with Bonferonni corrected levels of 
observed significance showed that importance of EWB domain at assessment 4 was 
significantly lower than that at assessment 2(p = 0.009). (Table 21) 
 






























.036 .021 .111 .932 .096 .003 
Note: a. Based on positive ranks. 
           b. Based on negative ranks. 
 
Domain Ranking Changes at Assessment Intervals 
No statistically significance in the ranking of FACT-B domains between the four 
assessments or within each assessments using Friedman's test (p>0.05). (Table 22 and 
Figure 17) 
 
Table 22. Mean Ranking of FACT-B Domains at 4 Assessments 
 FACT-B domains 
Assessments 
P-value 
1 2 3 4 
Physical Well-being 2.07  2.00  1.73  2.27  0.495 
Social/Family Well-being 2.47  2.40  2.87  2.47  0.666 
Emotional Well-being 2.47  2.47  2.53  3.00  0.201 
Functional Well-being 3.00  3.13  2.87  2.27  0.114 
P-value 0.266 0.114 0.052 0.356  
Note: 1: Assessment 1: Before surgery 
           Assessment 2: 2 weeks after surgery 
           Assessment 3: During chemotherapy 
           Assessment 4: 1 year after surgery 
            2. Figures in cell are mean ranking score of FACT-B domains. 
            3. Lower score represents higher importance. 
 









When participants were asked about the further concerns of the disease before 
surgery, financial concern was the most common concern mentioned except disease 
prognosis (20%, 3/15). At the later assessment period, the concerns were shifted to 
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4.5 Study V: Inflammatory Cytokines, Depression, Cancer and Ageing 
 
Characteristics of Participants 
2774 elderly subjects with inflammatory cytokine plasma sample were selected from 
SLAS main cohort with mean (SD) age of 66.3 (7.8) years. 31.3% (N=869) participants 
were aged 70 and above. 62.9% (N=1745) participants were female. 90.1% (N=2499) 
participants were Chinese. 3.0% (N=82) participants had cancer history. Overall GDS 
score was 1.0 (1.9), approximately 3.0% (N=84) had GDS ≥5 indicating moderate 
depression, and 2.0% (N=55) had GDS ≥ 9 indicating severe depression. 
 
Association of cytokine levels with cancer history 
Before adjustment, participants with cancer history, compared with their counterparts 
without cancer, were with significant lower level of TNF-α (Table 23). No other statistical 
significant differences were found between these two groups. 
 
However, after adjusting for age, gender, BMI, medical comorbidities and 





Association of cytokine levels with depression 
Elderly participants with depression, compared with their counterparts without 
depression, were more likely to be older, living in lower-end public housing, not married, 







     
Age, y Mean (SD) 67.5(8.3) 66.2(7.8) 0.161 
 ≥70 years 26(31.3%) 843(31.7%) 0.940 
     
Sex Female 59(72%) 1686(62.6%) 0.085 
     
Ethnicity Chinese 76(92.7%) 2423(90.1%) 0.678 
     
Housing status Public 1-2 room size 18(22.0%) 418(15.6%) 0.561 
     
Marital status Single, divorced, 
widowed 
33(40.2%) 883(32.8%) 0.561 
     
Ever smoker Yes 7(10.8%) 226(10.6%) 0.959 
     
Medical comorbidities Mean (SD) 0.3(0.5) 0.3(0.5) 0.899 
     
BMI Mean(SD) 24.0(3.5) 24.0(4.0) 0.890 
     
GDS Mean (SD) 1.1(2.2) 1.0(1.9) 0.787 
     
CRP (mg/l) Mean (SD) 28.5(70.3) 20.2(53.6) 0.288 
     
IL-6 (pg/ml) Mean (SD) 7.3(29.4) 2.2(10.0) 0.122 
     
TNF-α (pg/ml) Mean (SD) 24.5(53.3) 44.6(139.4) 0.009 
     
Figures shown are n (%) and mean (SD) 
*Data are presented as percentage of participants unless otherwise indicated. One-way 
analysis of variance, independent, 2-tailed t test was used for continuous variables (to 
determine the mean), and the χ² test was used for categorical variables (to determine the 
percentage). 
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ever smoker, with more medical comorbidities, worse QOL, poorer life satisfaction (p < 
0.05).(Table 24) Also, their TNF-α level was close to statistical difference compared with 
that of their counterparts (p=0.082). No other statistical significant differences were 
found between these two groups. 
 
After adjusting for age, gender, housing, marital status, smoking history, medical 
comorbidities and BMI, statistically significant difference of TNF- α level was found 












Age, y Mean (SD) 67.5(9.1) 66.2(7.8) 0.109 
 ≥70 years 55(39.6%) 814(30.9%) 0.032 
     
Sex Female 87(62.6%) 1658(62.9%) 0.937 
     
Ethnicity Chinese 125(89.9%) 2374(90.2%) 0.649 
     
Housing status Public 1-2 room size 40(29.0%) 396(15.1%) <0.001 
     
Marital status Single, divorced, 
widowed 
73(52.5%) 846(32.0%) <0.001 
     
Ever smoker Yes 22(21.4%) 211(10.0%) <0.001 
     
Medical comorbidities Mean (SD) 0.7(0.6) 0.3(0.5) <0.001 
     
BMI Mean(SD) 23.6(4.4) 24.0(4.0) 0.294 
     
SF-12 PCS Mean (SD) 43.2(10.1) 49.3(6.4) <0.001 
     
SF-12 MCS Mean (SD) 43.6(10.6) 55.7(6.7) <0.001 
     
LS Mean (SD) 11.4(3.1) 7.5(2.1) <0.001 
     
Cancer Yes 5(3.6%) 77(2.9%) 0.647 
     
CRP (mg/l) Mean (SD) 22.9(46.8) 20.3(54.5) 0.584 
     
IL-6 (pg/ml) Mean (SD) 2.3(6.2) 2.3(11.3) 0.977 
     
TNF-α (pg/ml) Mean (SD) 74.4(212.5) 42.5(132.4) 0.082 
Figures shown are n (%) and mean (SD) 
Depression was defined with GDS score ≥ 5. 
*Data are presented as percentage of participants unless otherwise indicated. One-way 
analysis of variance, independent, 2-tailed t test was used for continuous variables (to 
determine the mean), and the χ² test was used for categorical variables (to determine the 
percentage). 
 




After stratifying depression into three levels, TNF-α level was significantly 
associated with depressive level (p = 0.003). (Table 25) The association still exited after 
adjusting for confounding variables including age, gender, housing, marital status, 
smoking history, medical comorbidities and BMI. There were not significant associations 
between IL-6 or CRP with depressive levels.  
 
 
A Bonferroni post-hoc test revealed that TNF-α level was significantly higher in 
group of participants with severe depression (GDS ≥ 9) compared to the groups of 
participants without depression (GDS < 5) (p = 0.003). There were no statistically 
significant differences between non-depressed (GDS < 5) and moderate depressed (GDS 
5-9) groups (p > 0.05). 
 
Table 25. TNF-α, IL-6, CRP plasma levels stratified by GDS levels and ANOVA results. 
GDS Groups n Mean (SD) 5-95% ANOVA (p) 
TNF-α (pg/ml)     
        GDS < 5 2632 44.5 (132.4) 37.4-47.5 
P = 0.003         GDS 5-9 84 55.1 (123.3) 28.3-81.8 
        GDS ≥ 9 55 104.0 (301.0) 22.6-185.3 
     
IL-6 (pg/ml)     
        GDS < 5 2633 2.3 (11.3) 1.9-2.8 
P = 0.802         GDS 5-9 84 1.8 (3.0) 1.1-2.5 
        GDS ≥ 9 55 3.0 (9.1) 0.6-5.5 
     
CRP (mg/l)     
        GDS < 5 2628 20.3 (54.5) 18.2-22.4 
P = 0.861         GDS 5-9 84 22.9 (37.3) 14.9-31.0 
        GDS ≥ 9 55 22.8 (58.9) 6.8-38.7 
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Inflammatory cytokines, depression and Ageing 
After grouping participants according to their age (Age ≥ 70) and depression status (GDS 
≥ 5), the study sample was divided into four different groups: (1) young old without 
depression, (2) old-old without depression, (3) young-old with depression, and (4) old-
old with depression. Compared with other three groups, TNF-α level in Old-old with 
depression group were significantly higher after adjusting for confounding variables 
including gender, race, housing, marital status, smoking history, medical comorbidities 
and BMI. (Table 26) 
 
Correlations between inflammatory cytokines 
There was a very weak correlation between TNF-α and IL-6(r=0.054, p=0.004), and a 
very weak correlation between IL-6 and CRP (r=0.094, p<0.001), and non-significant 
correlation between TNF-α and CRP (p=0.661). (Table 27) 
 
TNF-α was positively correlated with medical comorbidities (r=0.313, p<0.001) 
and very weakly with GDS scores (r=0.060, p=0.002). IL-6 was also positively, but much 
weaker correlated with medical comorbidities (r=0.048, p=0.019). CRP was very weak 



















       
TNF-α (pg/ml) Mean (SD) 48.6(140.5) 40.7(134.9) 70.7(181.2) 78.6(254.9) 0.001 
       
IL-6 (pg/ml) Mean (SD) 1.7(5.8) 2.5(6.7) 1.5(2.1) 3.5(9.5) 0.095 
       
CRP (mg/l) Mean (SD) 19.5(53.7) 24.9(66.3) 14.6(21.7) 35.5(68.0) 0.659 
       
Depression was defined as GDS score ≥ 5. 
*One-way analysis of variance was used for continuous variables (to determine the mean). 
^Adjusting for gender, ethnicity, housing, marital status, smoking history, medical comorbidities, BMI 
Table 27. Correlation with  TNF-α, IL-6 and CRP  
Variables TNF-α (pg/ml) IL-6 (pg/ml) CRP (mg/l) 
IL-6 (pg/ml) 0.054 p=0.004** - - 
CRP (mg/l) 0.008 p=0.661 0.094 p<0.001** - 
Age (year) 0.005 p=0.810 0.007 p=0.725 0.059 p=0.002** 
BMI (kg/m
2)
 -0.010 p=0.619 0.023 p=0.231 0.130 p<0.001** 
Comorbidity 0.313 p<0.001** 0.048 p=0.019* 0.011 p=0.579 
GDS 0.060 p=0.002** -0.009 p=0.618 0.015 p=0.419 
** p<0.01; * p<0.05    
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As a subspecialty, research in Psycho-oncology[122, 123] generally addresses the 
two major psychological dimensions of cancer: the psychological, behavioural and social 
factors that may influence the disease process (called psychosocial-oncology)[124-126]; 
and the psychological responses of patients to cancer at all stages of the disease 
(called oncopsychology)[127-129]. Based on this definition, the current thesis consisted 
of three major parts: firstly, on psychosocial-oncology dimension, study I & II to explore 
the potential association between psychological factors (poor mental health functioning 
and depressive symptoms) and cancer incidence / survival; secondly, on oncopsychology 
dimension, study III & IV to demonstrate the psychological responses of cancer patients 
in short-term and long-term follow-up with addressing the possible problem of repeated 
QOL assessments in longitudinal study; and finally, study V to explore the psycho-neuro-
immunological model between depressive symptoms, cancer and ageing through 
inflammatory cytokines. 
 
5.2 Study I: Psychological Status and Cancer Incidence 
 
In this population-based prospective cohort study of cancer risk in an Asian older 
adult population, we found that poor self-reported mental health was significantly 
associated with an estimated 42% increased risk of incident cancer from 6 years of 
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follow-up after controlling for age, gender, socio-economic status, smoking, BMI and 
medical comorbidity. Reported findings on the relation between psychological and 
mental health variables and cancer risk are controversial and mixed.Two meta-analyses 
published in 1994 and 2007 [37, 38] suggested a tendency towards a small and 
marginally significant association between depression and subsequent overall cancer 
risk (pooled relative risk of overall cancer: 1.12, 95% C.I. 0.99-1.26). However, these 
studies showed substantial heterogeneity of effects across studies, and involved largely 
younger adults. The risk of cancer overall increases exponentially with age, and there 
had only been one other study (the Established Populations for Epidemiologic Studies of 
the Elderly, Penninx et al, 1998) which followed up an elderly cohort aged 71 to 96 years. 
That study reported a higher relative risk of overall cancer associated with chronically 
depressed mood of 1.88 (95% C.I., 1.13-3.14), similar to the higher estimate of relative 
risk of cancer associated with poor mental health status in this study of older adults. Our 
findings are also in accord with the most recent Baltimore Epidemiologic Catchment 
Area (ECA) Study which was published (2010) after the latest meta-analysis in 2007, and 
had the longest 24 years of follow-up. It reported that major depression was associated 
with a higher risk for overall cancer (HR: 1.9, 95% CI: 1.2, 3.0) and a statistically 
significant increased hazard for breast cancer (HR: 4.4, 95% CI: 1.08, 17.6) among 
women.  
 
There are differences in the cellular and molecular mechanisms of cancer 
development [22-24] at younger and older age. Ageing is associated with not only an 
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accumulation of oncogenic mutations, but also a deteriorating immune defense 
mechanism against cancer [130]. In older adults, a progressive decline in immune 
function due to a down regulation of specific immunity and a nonspecific activation of 
pro-inflammatory pathways [25, 131, 132] result in impaired cell-mediated and humoral 
immune responses, a generalized increase of immune-inflammatory response [33] and 
an increased susceptibility to infections and cancer. At the same time, studies have 
demonstrated that patients with depression exhibit characteristic signs of immune 
dysregulation[133] as well as increased levels of pro-inflammatory cytokines such as 
interleukin-6 (IL-6). [134] A chronic depressive state may therefore favor the 
development and exacerbation of cancers, especially in the elderly. Another possible 
biological mechanism is that depression inhibits DNA repair mechanisms and thus 
favours cancer growth[135]. Depression may also increase the risk of cancer through a 
dysregulation of the hypothalamic–pituitary–adrenal axis and the levels of the stress 
hormone cortisol, which is involved in the control of cell growth and regulation of the 
cell cycle.[136, 137] A flattening of cortisol levels throughout the course of a day has 
been shown to increase the risk for breast cancer [138]. There are contradictory reports 
that the use of antidepressants may have the potential to increase the risk of cancer 
development, [139] or preventing certain cancers.[140] Finally, depression and poor 
mental health is commonly associated with behaviours such as physical inactivity, 
smoking, and high fat and calorie consumption that indirectly increase the risk of 
developing cancer. Our analysis adjusted for body mass index, smoking and chronic 
medical conditions, but this did not change the estimates of association.  




 A principal methodological issue in establishing the link between mental health 
functioning (depression in particular) and cancer risk is the problem of measuring the 
changing mental health states which are altered by a variety of stress factors and 
physical health conditions common in the elderly. The hypothesis that a long-term 
dysphoric state contributes to or exacerbates cancers is most likely to be supported if 
the study subjects have depressive symptoms or disorders that are persistent or chronic. 
Most studies including ours used a single measurement on one occasion to assess 
depressed mood or mental health state. Large national registry-based or insurance-
based cohort studies [35] that have used diagnostic manual in psychiatry (the 
International Classification of Diseases, ICD or the Diagnostic and Statistical Manual of 
Mental Disorders, DSM) for a one-time baseline diagnosis of depression similarly failed 
to support an increased risk of cancer. Furthermore, a substantial body of evidence 
shows that a majority of depressed individuals do not fulfill diagnostic criteria for 
depression, yet still manifest clinically significant depressive symptoms that have been 
described in literature as minor, subsyndromal or subthreshold depression, but are 
known to be just as disabling as syndromal depression. [141] Exposure misclassification 
into “normal” control study population may thus have the effect of weakening or even 
eliminating the association between depression and cancer risk.  
 
For these reasons, it is not surprising to find that the GDS used in the present 
study failed to predict cancer risk. We observed however that the SF-12 MCS measure of 
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mental health status successfully predicted subsequent cancer risk over 6 years. There is 
a substantial overlap between concurrently measured levels of SF12-MCS and GDS 
depression score, but the strength of SF-12 MCS is that it provides a more stable 
measure of the mental health status over a longer term (measures mental health over 
the past month) than GDS (measures depressive symptoms over the past week). In 
addition, SF-12 MCS provides measurement on different domains of mental health 
functioning, not only depressive symptoms. Given that, the effect of SF-12 MCS in 
predicting an increased risk of cancers may also be due to the contribution of other 
psychological variables such as stress or anxiety. The SF-12 MCS and PCS measures of 
patient-reported health status and function have been demonstrated to be able to 
quantify underlying aspects of health not captured by conventional measures of disease 
severity or other risk factors. It is commonly used as a prognostic or risk stratification 
tool [142] for independently predicting adverse outcomes, including mortality, for 
example in studies of cardiac patients.[143] Current evidences from literature which 
focused mainly on depressive symptoms or disorders may ignore the significance of 
other domains of mental health. Further studies should establish the validity of using 
the SF-12 MCS as a prognostic marker of the risk of cancer development in different 
patient and population groups.    
 
5.3 Study II: Depression and Cancer Mortality 
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Despite the numbers of studies in recent decades conducted to investigate the 
association between depression and mortality among cancer survivors with various 
cancer types, [44, 45, 48-52, 144] the results are mixed and the association remains 
controversial. A recent meta-analysis summarizing the most extant evidence up to 2009 
presented reasonable evidence that depression predicts mortality in cancer patients 
[47]. Based on data from 25 independent studies, mortality rates were up to 25% higher 
in patients experiencing depressive symptoms (RR unadjusted = 1.25; 95% CI, 1.12-1.40; 
P < .001), and up to 39% higher in patients diagnosed with major or minor depression 
(RR unadjusted = 1.39; 95% CI, 1.10-1.89; P = .03). This represents a consistent but small 
effect of depression in predicting mortality among cancer patients. Our study findings 
stand out in showing substantially (four times) higher mortality risks associated with 
depression (sub-threshold and threshold) among long-term cancer survivors compared 
to their counterparts without depression, This supports a persistent effect or potential 
cumulative effect of depression on cancer survival.  
 
It is noteworthy that the survival times between cancer survivors with / without 
depression before our interview were not significantly different. Both of the survival 
times before our interview were more than 10 years, which were sufficiently considered 
by clinician as cancer-free. However, those cancer survivors who suffered from 
depression when interviewed have been demonstrated to have shorter survival time 
compared to their age-matched, non-depressed counterparts. These concerns has been 
raised by some researchers that both the physical and psychological domains of quality 
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of life are often neglected in long-term survivorship when patient encounters with the 
health-care system become less frequent.[145] Psychological support / intervention for 
long-term cancer survivors may stand a chance to translate into promising benefits in 
cancer survivorship through the collaboration of researchers, clinicians, and experts in 
the field. 
 
Compared to previous studies, the considerably higher mortality risk associated 
with depression among cancer survivors observed in this study may be attributable to 
their much older age, long follow up period, and the higher prevalence of clinical 
depression based on diagnostic interview.  The average age of the cohort at 72 years 
was considerably older than the average age (55 years) in previous studies, and the 
length of follow up at 19 years post cancer diagnosis was also considerably longer. 
Depression diagnosis was made on average about 11 years post cancer diagnosis, hence 
the mortality risks represent long-term mortality of cancer survivors. Given their 
advanced age and follow up period (approximately 8 years), nearly half the cancer 
survivors (28/61) died during the follow up period, hence there were reasonably large 
numbers of deaths for reliable estimates of their mortality hazards.  
 
Another major strength of this study is the diagnosis of depression made with a 
standardized field diagnostic instrument (the Geriatric Mental State), with diagnosis of 
depression made by means of a computer-assisted system algorithm, AGECAT. [104] 
Prior studies using the GMS-AGECAT have consistently demonstrated it to provide 
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accurate diagnoses of recent psychiatric disorders in elderly people meeting clinical 
criteria for DSM-IV diagnosis of major depression. In the meta-analysis report by Satin et 
al in 2009, consistently, estimates of mortality risks associated with depression among 
cancer survivors in these studies were lower for depressive symptoms than for clinical 
grade depression. The meta-analysis determined that 25 independent studies of 
mortality risks in cancer survivors were based on measures of depressive symptoms, 
and only 3 independent studies relied on clinical interviews based on the Diagnostic and 
Statistical Manual (DSM-III-R and DSM-IV) to confirm the presence of major or minor 
depressive episode. Two of the three studies reported hazard ratios, and together they 
gave a combined HR (adjusted) estimate of 1.67 (95% CI, 0.96-2.90, P=.07). However, 
the mean age of the cohort in one study was 35.4 years, and in the other study was 
unknown.  
 
In this study, the mortality hazard estimates were controlled for confounding by 
a number of known risk factors, including demographic characteristics, social economic 
status, smoking history and medical comorbidities. Adjusting for these known clinical 
prognostic factors did not weaken the estimates of mortality effect of depression among 
cancer survivors. The study cohort involved a nationally representative population 
sample, and the participants’ past cancer diagnosis was accurately determined from the 
national cancer registry. The cancer diagnoses in this study therefore represent a 
broadly representative mix of cancer types. In contrast, almost all previous studies have 
either involved a single cancer type or selected cancers, contributing to the reported 
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heterogeneity of results. The increased mortality associated with depression among 
female breast cancer survivors (HR=11.6, 95%CI: 0.69-194.1, p=0.089) is particularly 
noteworthy, although based on small numbers, since hormone-related cancers are more 
susceptible to influences by psychological factors, given the involvement of the immune 
system.  
 
The higher prevalence of threshold depression (6.7%) among cancer survivors in 
this study cohort compared to participants who were never diagnosed to have cancer 
(3.5%) is consistent with previous estimates of the prevalence of serious psychological 
distress reported elsewhere. The prevalence of sub-threshold depression was three-fold 
higher in both cancer survivors and their non-cancer counterparts. Depressive 
symptoms or sub-syndromal depression in older people have been found in many 
studies to be similar to threshold level depression with respect to health and service 
utilization outcomes including functional dependency, quality of life, perceived need 
and utilization of health services. [13] Sub-threshold depression is often overlooked or 
accepted as a normal part of ageing, especially in those with co-morbid chronic medical 
illnesses including cancer. Interestingly, we found no significant difference between 
threshold or sub-threshold depression with respect their associated mortality risks 
among the cancer survivors. Limited statistical power due to small sample size may 
contribute to the negative finding. 
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In this study, the mortality risk of cancer survivors with depression was 
investigated in an elderly population. Ageing is associated with not only an accumulation 
of oncogenic mutations, but also impaired cell-mediated and humoral immune 
responses with resulting susceptibility to infections and cancer [130]. A down regulation 
of specific immunity and a nonspecific activation of pro-inflammatory pathways [25, 131, 
132] manifested by characteristic markers of immune dysregulation[133] and increased 
levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) [134] is also observed in 
depression. A chronic inflammatory state associated with depression may therefore 
favor the exacerbation of cancers, or increase multisystem depletion of physiological 
reserves resulting in physical frailty and adverse health outcomes including cancer.[26, 
27, 33, 146, 147] Furthermore, depression is commonly associated with behaviours such 
as physical inactivity, smoking, and high calorie and fat consumption that indirectly 
increase the risk of death. However, our analysis adjusted for smoking and chronic 
medical conditions, but this did not alter the estimates of association.  
 
This study has some limitations. Although the parent cohort was a national 
representative sample of Singapore population, the number of cancer survivors within 
this sample was relatively small. This small sample may possibly not be a true 
representative of our target population, which precludes the precise assessment of 
mortality risk associated with depression separately for different cancer types and to 
test the potential moderating effects of cancer stage, cancer grade, and other variables. 
We did not have data on cancer classification and grading because a detailed cancer 
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registry system was not established until 2004. We determined depression status only 
once at the start of the study, hence any prior or subsequent change in psychological 
status and its impact on mortality could not be assessed.   
 
Our results indicate that clinical depression and depressive symptoms are 
important predictors of mortality among older long-term cancer survivors. Generally 
oncologists are in agreement that the psychological health of cancer survivors is an 
important element of patient care. However, currently it remains unclear to what extent 
the formal assessment of psychological health contributes towards cancer 
prognostication. Our result is the most indicative so far that the diagnosis of clinical 
depression and the presence of significant depressive symptoms among cancer 
survivors are prognostic indicators of future life expectancy. It underscores the 
significant adverse health status and quality of life known to be associated with 
depression when present among cancer survivors. The significantly prevalence of 
syndromal and sub-syndromal depression among cancer survivors should therefore not 
be under-estimated.  
 
5.3 Study III & IV: Quality of life and Response Shift Phenomena 
 
5.4.1 Study III: Quality of Life in Long-term Cancer Survivors 
 
In this community living elderly population, we found that QOL in long-term cancer 
survivors is not different from their age-matched non-cancer counterparts after 
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adjusting for demographic characteristics and medical comorbidities. Long-term cancer 
survivors adapted well physically as well as psychosocially to their once mortal illnesses. 
 
Consistent with several previous reports [58, 61-64], Singaporean community living 
cancer survivors have at least equivalent, if not better, QOL than the age-matched 
general population many years after the immediate period following primary treatment 
(6 months to 2 years). Not having different level of depression and social support 
similarly suggested they have been living as “normal” as an ordinary elderly without 
cancer history. Like many other developed countries, Singapore government has funded 
a range of programs to assist cancer patients and their families, such as helplines, cancer 
support groups, information on cancer in hospitals and health centres. Well-trained 
health practitioners also helped adopt the best available methods of treatment through 
their clinical practice guidelines. All these efforts have helped cancer survivors and their 
families to cope well with their diseases, and those initial interventions have a real 
impact on QOL which can last for many years. As the concern of the government 
services providers and professional researchers, cancer survivors who remain free of 
disease probably do not need advanced/systematic late psychosocial follow-up to 
improve QOL as patients or some social workers worry about.  
 
A major problem in assessing QOL in long-term cancer survivors is distinguishing 
effects due to cancer and its treatment from those due to ageing and comorbidities, 
since the probability of having a chronic disease or functional limitation increases with 
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advanced age.  In our study, QOL assessment was conducted by using SF-12, a 
structured questionnaire developed for general population. It is based on the hypothesis 
that long-term cancer survivors adapted well after their critical phase of disease and 
treatment (6 months to 2 years). It is proved by many psychological studies that human 
beings have an amazing capacity to meet and to adapt to challenges they face, and long-
term cancer survivorship exemplifies the strength of the body and spirit.[148-153] The 
aspects of QOL that pose the most difficulty for survivors varies by cancer site. Cancer-
specific QOL assessments including treatment-specific concerns are designed for use 
during therapy. Those assessment tools may not be relevant in healthy survivor 
populations. On the other hand, questionnaires initially developed for a healthy 
population may omit symptoms that continue to be important to cancer survivors. It is 
recommended that future investigators to consider using a generic core questionnaire in 
conjunction with supplementary items or scales to address specific concerns when 
assessing QOL in long-term cancer survivors.  
 
Our study is unique in that it is one of the first researches that compare 
community living long-term cancer survivors to age matched controls with ageing and 
medical comorbidity taken into account. Limitations include the small sample size of 
cancer survivors, cross-sectional study design which limited us from drawing causality 
conclusions. Furthermore, our study does not focus on specific concerns of various 
cancers which may omit site-specific physical/psychological needs of cancer survivors, 
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and does not collect information on details of initial systematic cancer treatment, which 
may limit the generalizability of our results.  
 
In conclusion, long-term cancer survivors have similar QOL to their age-matched 
non-cancer controls in this Singaporean community living elderly population. Further 
research is needed to get a better understanding of the psychological adaptation 
process, to provide a more comprehensive and complete perspective on the needs of 
long-term cancer survivors, to address methodological issues in long-term survivorship 
research and to develop a better QOL assessment tool to identify who is most in need of 
and likely to benefit from late follow-up psychosocial intervention. 
 
5.4.2 Study IV: Response Shift Phenomena in Breast Cancer Patients 
 
In this local Singaporean female breast cancer population, our study provided 
some preliminary support for the existence of response shift phenomenon in the first 
year of patients’ disease trajectory. Response shift phenomenon – change in internal 
standards (i.e. “recalibration”) was mainly observed when patients were going through 
chemotherapy period. Physical Well-being, Emotional Well-being and Additional 
Concerns about breast cancer were the most affected domains of QOL assessments. 
Response shift reaction – change in values (i.e. “repriorization”) and conceptualization 
(i.e. “reconceptualization”) of QOL was mainly observed after one year follow-up.  
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Breast cancer patients were selected based on the fact that it is the most common 
female malignancy in the West as well as in Singapore[154]. More than 1.3 million 
women are diagnosed with breast cancer worldwide every year. With significantly 
increased survival rate, vast numbers of women with breast cancer survive from cancer, 
but continue to experience considerable physical and psychosocial dysfunction following 
treatment which attracted the attention of clinicians, researchers, health professionals. 
 
As an indispensable part of cancer outcome now, Health Related Quality of Life 
(HRQOL) has been repeatedly conducted in clinical practices. One of the challenges in 
using HRQOL as an outcome in longitudinal studies or clinical trials is that as people 
experience changes in their physical health owing to improvement or more commonly 
to deterioration, or owing to an intervention, they change their values and rerate the 
importance of basic elements of HRQOL, which is related to their self-report nature and 
also to their subjectivity. In 2013, the French National Platform of Quality of Life and 
Cancer and the statistical team of the Mathematical Institute of Luminy undertook the 
first conference addressing the statistical challenges of measuring the quality of life in 
the field of oncology. One of the three main topics focused on this conference was 
detection and understanding of response shift.[155] Response shift as a potential 
confounder was recently provided in a study suggesting that this bias may occur in at 
least 70% of participants of self-management interventions.[156] However, to date, 
there have been only a few studies in the field of cancer that extensively examine the 
correlation between changes in QOL whilst attempting to capture the occurrence of 
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response shift. In addition, the majority of the studies examined response shift in the 
areas of fatigue, radiotherapy, and surgery, and does not capture the occurrence of 
response shift longitudinally during the course of patients’ disease trajectory.[157] 
Judgment theories explained the change of patients’ internalized standards of 
perception and conceptualization of QOL dimensions when facing a life-threatening 
disease. Thus a real effect, for example a decrease in QOL as a result of cancer, can be 
substantially underestimated or obscured totally, which is consistent with our research 
findings. 
 
Our study described the changes of QOL over four assessment intervals and 
suggested the occurrence of response shift at critical phases of patients’ disease 
treatments trajectory. All three dimensions of response shift bias have been suggested 
at different phases of treatment trajectory during one year follow-up.  
 
It is also suggested that a significant change in patients’ internal standard 
(recalibration) occurred after surgery and during chemotherapy - the two most critical 
phases of breast cancer treatments, which well reflected the above response shift 
theory. Patients have reported much worse QOL than their concurrently assessed QOL 
during these phases. Physical well-being, emotional well-being and specific concerns 
about breast cancer are the affected domains contributing to recalibration during 
chemotherapy, while social well-being is the domain affected at the phase of post-
surgery.  




Change in values (repriorization) and conceptualization (reconceptualization) of 
QOL were suggested by our study at the phase of one year follow-up (post-
chemotherapy). Patients have changed the importance of physical, emotional and 
functional domains of QOL after all the treatments have been completed. After 
experiencing of life and death, most patients have shifted their concerns from financial 
aspect to spiritual concerns, career prospective and mental health after one year. It is 
not surprised to hear stories about people who convert from atheism to certain religion 
after a life-threatening illness. Psychological and spiritual needs seem more demanding 
after all cancer treatments have been conducted. When facing an uncertain future of 
cancer, patients can only try as far as possible to seek inner peace. 
 
While response shift is not new from a clinical or intuitive perspective[158], it is a 
relatively new phenomenon from a methodological and theoretical viewpoint. 
Methodologically, shifting internal criteria, values, and conceptualization of life may 
render assessments completed over time incomparable, and as a result, the comparison 
itself has lost its meaning.  
 
There are currently no guidelines available for researchers on how to measure 
response shift in HRQOL evaluations and to account for response shift in the estimation 
of change. The simplest and most common design to assess response shift bias is Then-
Test design including a pretreatment and a post-treatment assessment.[159-162] 
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Despite its popularity, simplicity and amenability to a trial context, then-test approach 
has some limitations. Then-test approach purports to address mainly changes in internal 
standards (recalibration) and recall bias may also affect the reliability of this assessment 
approach. Card sort game, as another approach used in our study, was successfully used 
in predicting repriorization and reconceptualization dimensions of response shift. This 
approach, from our experience, is simple to use and easy to be analyzed statistically.  
However, to reliably use this approach, certain level of knowledge and education was 
required. It may limit the generalization of this approach in assessing response shift 
phenomenon. Except that, Schwartz and Sprangers[113] have also described a range of 
promising assessment approaches for measuring response shift in observational and 
interventional clinical research, including individualized methods, preference-based 
methods, design approaches, statistical approaches, and qualitative approaches. 
Research substantiating and triangulating a number of these methods is currently still 
underway. 
 
Strengths of this study include a longitudinal research design, homogeneous 
population-based cohort, and the wide range of QOL domains that were assessed. 
Although a relatively small sample size was recruited for this study, a response shift bias 
has been supported through one year follow-up. The authors also wanted to remind 
that recall bias is the inevitable condition when Then-test design was used. The study 
was also greatly limited in its power due to relatively small sample size. 
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In conclusion, response shift probably affecting breast cancer patients at different 
phases of treatment may have an important impact on the interpretation of changes of 
HRQOL reported in clinical trials. Unfortunately, most studies in the literature focused 
on the question of whether or not response shift occurred and how to detect it using 
one method rather than a more informative approach of how to adjust for it or 
minimize bias in longitudinal analysis when it occurred. An important aspect for future 
research is to investigate how to deal with response shift for statistical analyses of 
longitudinal HRQoL. At the same time, clinicians and caregivers should be aware of the 
fact that patients’ physical and psychological needs may be underestimated based on 
their self-reported QOL. 
 
5.5 Study V: Inflammatory Cytokines, Depression, Cancer and Ageing 
 
In this community-living Singaporean elderly population, we observed significant 
association between depression levels and inflammatory cytokine TNF-α concentration, 
while IL-6 and CRP was not proved to be associated with depression. In addition, we 
found that levels of TNF-α and IL-6 increased with medical comorbidities, and that age 
and BMI had significant influence on plasma level of CRP. Older senior participants with 
depression had a much higher level of TNF-α than that of other community living seniors. 
 
Depression is an important and common public health issue in elderly population. 
The impact of depression on quality of life is comparable with or greater than that of 
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other chronic medical illness.[163] Consistent with our findings as expected, depressed 
seniors have worse physical / psychological quality of life and lower level of life 
satisfaction. Older age, worse social economic states, worse marital states and suffering 
from more medical comorbidities may all contribute to their depressed psychological 
condition. Studies suggest that depression is accompanied by immune dysregulation and 
activation of the inflammatory response system, which has been demonstrated by 
increased production of pro-inflammatory cytokines and proteins such as IL-6, TNF-α 
and CRP.[32, 89, 164-167] 
 
Similar with depression in inflammatory response, chronic low-grade inflammation 
in ageing is believed to be related to age-associated disorders and an enhanced 
mortality risk, and it has now been accepted as a major risk factor for carcinogenesis. 
Emerging evidence shows that TNF-α has key roles in this process.[168] 
 
TNF-α and IL-6 are pro-inflammatory cytokines secreted by a variety of cell types 
and tissues, including tumor cells. Both cytokines can stimulate the hepatocyte-derived 
acute phase protein CRP. Our research finding also supports such correlation between 
TNF-α, IL-6 and CRP.  However, the correlation appeared to be very weak. 
 
TNF-α, IL-6 and CRP have been found elevated in several types of cancer,[169-171] 
which are also proved increased in depressed patients.[89] Our finding clearly 
demonstrated the association between levels of depression and elevated levels of TNF-α 
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concentration. However, no evidence is found from our study to support the link 
between depression and IL-6 / CRP. There have been several other studies that have 
examined circulating cytokines and CRP with inconsistent results.[172-177] The possible 
reason for such different conclusions, in our opinion, lies in the different study sample 
and definition of depression. We examine the serum inflammatory cytokines in a senior 
population with mean age above 65, who is already at high level of inflammatory 
cytokines production due to ageing, multiple comorbidities and increased body weight. 
On the other hand, different studies have used a variety of criteria on the definition of 
depression. We have used a symptomatic depression assessment tool instead of clinical 
diagnosis to stratify different levels of depression based on the understanding that 
majority of depressed seniors do not meet the criteria of clinical diagnosis[98] but still 
suffer from this psychological abnormality[6, 7]. 
 
Not to our surprise, the older senior participants (aged 70 and above) with 
depression has reported the highest serum level of TNF-α, further suggesting that 
dysregulated production of inflammatory cytokines play a similar important role in the 
process of ageing as well as depression. In another word, depression may further 
aggravate our body’s inflammatory burden of ageing and become the last straw that 
breaks the camel’s back. 
 
Strengths of this study include that large community living senior sample has been 
used to get a relatively homogeneous study population. In addition, standardized 
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interviewing and valid, objective measures were used for assessment of study variables 
and biomarker concentration. A weakness of this study is that only one assay was used 
to assess TNF-α, IL-6 and CRP levels while variations between methods may occur. 
Additionally, it is known that variation may occur between commercial kits. Therefore, 
comparisons between other studies are difficult. Finally, the authors cautioned that 
current study was using cross-sectional study design that draws no conclusions about 
cause and effect.   
 
In summary, inflammatory cytokine TNF-α plasma level increased significantly with 
depression, providing insights into factors influencing the cytokine levels and the 
evidence base for supporting the hypothesis that psychological intervention may 
enhance functional immunity, and confer survival benefits.  
 
Strengths and limitations 
 
Research on the psycho-neuro-immunology model of cancer is novel to the field of 
cancer therapy and psychology. There is still no gold standard for evaluating both 
psychological variables and immunological variables. Two important limitations of these 
studies are the small sample size and study duration. Compared to large sample size and 
prospective study design in western countries, Singaporean limited population may 
restrict the generalization of our findings and relatively small sample size (especially in 
study II&III) may limit our possibility to address certain associations due to lack of power. 
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Before definitive conclusions can be drawn, these findings should be replicated with 
larger samples and over longer periods of time. Other factors, including the over-
representation of Chinese population, majority of participants not well educated and 
only a small proportion of all cancer patients that were screened for these studies, may 
also limit the generalization of the results. 
 
Implication of findings 
 
STUDY I & II: The study adds to a clear understanding of the relationship between 
mental health status and cancer risk and survival in older Singaporeans and may support 
evidence-based initiatives for psychosocial therapy and supportive care. 
 
STUDY III & IV: The study provides a better understanding on the psychosocial and 
quality of life status of cancer patients, so as to fill an important need in developing and 
improving the standard and quality of psycho-oncology services in Singapore, and 
spearhead innovations in psychotherapeutic interventions that are demonstrably 
effective and feasible in routine practice.  
 
STUDY V: The study provides insights on the influencing factors of inflammatory 
cytokines and the evidence base for supporting psycho-neuro-immunological model 
between cancer, depression and ageing. Based on this model, future psychological 
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interventions may improve immunological functioning, which, in turn, could translate 
into increased lifespan in the elderly population. 
 
Recommendation and future studies 
 
These studies suggest a possible link between psychological and social factors, cancer 
and immune functioning in the elderly population. This provides a basis for postulating 
new hypotheses regarding psychoneuroimmune-based mechanisms underlying 
psychosocial interventions to promote cancer early detection and to improve cancer 
outcomes. Longer follow-up time and larger sample size is suggested to determine 
whether psychological and immunological changes are related to functional health 
status and long-term disease-free survival. 
 
CHAPTER 6: SUMMARY AND CONCLUSION 
 
Older adults suffering from poor mental health were suggested to have an 
increased cancer incidence, more obviously in female breast cancer and male lung 
cancer. Older long-term cancer survivors were at high risk of being depressed than their 
counterparts without cancer history. Depression may shorten their life expectancy, and 
could be a prognostic marker of cancer survival. Long-term cancer survivors reported 
similar QOL to their age-matched non-cancer controls in Singaporean community living 
elderly population. Response shift clearly affecting cancer patients at different phases of 
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treatment may have an important impact on the interpretation of changes of HRQOL 
reported in clinical trials. Increased level of inflammatory cytokine TNF-α in Singaporean 
elderly population with depression, provides some limited support in explaining the link 
between depression and cytokines.  
 
In conclusion, this thesis provides insights and preliminary evidence base for 
supporting the hypothesis that psychological intervention may enhance functional 
immunity, possibly be protective against the development of cancers in late-life and 
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Appendix 6: Card Sort Game – Subgroups (FACT-B) 
 
